write notes for topic of viral hepatitis including jaundice therapeutics 3 it should include intro definition etiology pathophysiology in flowchart clinical features diagnosis treatment goals non pharmac treatment pharmacological treatment including drug short intro class short moa in flowchart drug interaction adr dose indication contraindication and summary chart for pharmacological treatment https://pharmdguru.com/viral-hepatitis-including-jaundice/ use this link too with extra source too
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
write notes for topic of viral hepatitis including jaundice therapeutics 3 it should include intro definition etiology pathophysiology in flowchart clinical features diagnosis treatment goals non pharmac treatment pharmacological treatment including drug short intro class short moa in flowchart drug interaction adr dose indication contraindication and summary chart for pharmacological treatment https://pharmdguru.com/viral-hepatitis-including-jaundice/ use this link too with extra source too
Reading File
Reading Web Page
https://pharmdguru.com/viral-hepatitis-including-jaundice/
Searching the Web
viral hepatitis pharmacological treatment drugs MOA ADR dose contraindications therapeutics
Finding Sources
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC8218370
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Running Command
mkdir -p /tmp/workspace/viral-hepatitis-notes && ls /tmp/workspace/
Writing File
~/viral-hepatitis-notes/viral_hepatitis_notes.md
# VIRAL HEPATITIS INCLUDING JAUNDICE
### Therapeutics 3 — Complete Study Notes
---
## 1. INTRODUCTION
Viral hepatitis is one of the most common and significant infectious diseases worldwide, representing a major global health burden. The WHO estimates that over 354 million people worldwide live with chronic hepatitis B or C, and hepatitis-related liver disease accounts for approximately 1.1 million deaths annually.
Viral hepatitis refers to inflammation of the liver specifically caused by hepatotropic viruses (HAV, HBV, HCV, HDV, HEV). These infections may present as:
- **Acute hepatitis** – self-limiting illness lasting <6 months
- **Chronic hepatitis** – persistent infection >6 months (HBV, HCV, HDV)
- **Fulminant hepatitis** – massive hepatic necrosis with acute liver failure
**Jaundice** (icterus) is a cardinal manifestation of viral hepatitis and results from hyperbilirubinemia. It is the yellow discoloration of the skin, sclera, and mucous membranes visible when serum bilirubin exceeds **2–3 mg/dL** (normal: 0.2–1.2 mg/dL).
---
## 2. DEFINITION
| Term | Definition |
|------|-----------|
| **Viral Hepatitis** | Inflammation of the liver parenchyma caused by one of five hepatotropic viruses (HAV, HBV, HCV, HDV, HEV), leading to hepatocellular injury, necrosis, and impaired liver function |
| **Acute Hepatitis** | Liver inflammation lasting <6 months, usually self-limiting |
| **Chronic Hepatitis** | Persistent hepatic inflammation >6 months; may progress to cirrhosis and hepatocellular carcinoma |
| **Jaundice** | Yellow discoloration of skin/sclera due to bilirubin accumulation in tissues; serum bilirubin >2.5–3 mg/dL |
| **Icteric Phase** | Clinical phase where jaundice is clinically apparent |
| **Fulminant Hepatitis** | Severe acute hepatic necrosis with hepatic encephalopathy developing within 8 weeks of symptom onset |
---
## 3. ETIOLOGY
### 3.1 Hepatotropic Viruses — Comparison Table
| Feature | **HAV** | **HBV** | **HCV** | **HDV** | **HEV** |
|---------|---------|---------|---------|---------|---------|
| **Virus family** | Picornaviridae | Hepadnaviridae | Flaviviridae | Deltaviridae | Hepeviridae |
| **Genome** | ssRNA (+) | dsDNA (partially) | ssRNA (+) | ssRNA (−) | ssRNA (+) |
| **Transmission** | Fecal-oral | Parenteral, sexual, vertical | Parenteral (mainly) | Parenteral (co/superinfection with HBV) | Fecal-oral |
| **Incubation** | 2–6 weeks | 6 weeks–6 months | 2 weeks–6 months | 3–7 weeks | 2–9 weeks |
| **Chronicity** | None | 5–10% adults; 90% neonates | 55–85% | High in superinfection | None (except immunocomp.) |
| **Vaccine** | Yes | Yes | No | Prevented by HBV vaccine | Yes (some countries) |
| **Severity** | Mild–moderate | Variable | Usually mild acute, chronic severe | Most severe form | Mild (severe in pregnancy) |
### 3.2 Risk Factors
**HAV/HEV (Fecal-Oral Route):**
- Contaminated food/water
- Travel to endemic areas
- Poor sanitation, overcrowding
- Close contact with infected persons
**HBV/HCV/HDV (Parenteral/Bloodborne):**
- Intravenous drug use (IVDU)
- Unprotected sexual intercourse (esp. HBV)
- Needlestick injuries (healthcare workers)
- Blood transfusions/organ transplants (pre-screening era)
- Vertical transmission (mother to neonate) — HBV
- Tattooing, body piercing with unsterilized equipment
---
## 4. PATHOPHYSIOLOGY
### 4.1 Pathophysiology of Viral Hepatitis — Flowchart
```
VIRAL ENTRY
│
▼
Virus gains entry via:
HAV/HEV → Ingestion → GI tract → Portal circulation → Hepatocytes
HBV/HCV/HDV → Blood/sexual/vertical → Systemic circulation → Hepatocytes
│
▼
VIRAL REPLICATION IN HEPATOCYTES
│
▼
Viral antigens expressed on hepatocyte surface
│
▼
IMMUNE RECOGNITION
│
├──► CD8+ Cytotoxic T Lymphocytes (CTL) attack infected hepatocytes
│ → Hepatocellular NECROSIS
│
└──► CD4+ Helper T cells → Cytokine release (TNF-α, IFN-γ, IL-2)
→ Inflammation → Hepatic INFLAMMATION
│
▼
HEPATOCELLULAR INJURY
│
├──► ↑ AST, ALT (hepatocellular necrosis markers)
│
├──► ↓ Protein synthesis → ↓ Albumin, ↓ Clotting factors
│
└──► ↓ Bilirubin conjugation and excretion
│
▼
JAUNDICE (Hyperbilirubinemia)
│
▼
OUTCOMES:
├──► RESOLUTION (HAV, HEV; most HBV in adults)
│
├──► CHRONIC HEPATITIS (HBV 5-10%, HCV 55-85%, HDV)
│ │
│ ▼
│ Continued inflammation → Fibrosis → CIRRHOSIS
│ │
│ ▼
│ Hepatocellular Carcinoma (HCC)
│ Portal Hypertension
│ Liver Failure
│
└──► FULMINANT HEPATITIS (rare) → Acute Liver Failure → Death/Transplant
```
### 4.2 Pathophysiology of Jaundice — Flowchart
```
BILIRUBIN METABOLISM (Normal):
Heme (from RBC breakdown) → Biliverdin → Unconjugated Bilirubin (UCB)
│
▼
UCB travels in blood (bound to albumin) → Liver uptake
│
▼
Hepatic conjugation: UCB + Glucuronic acid → Conjugated Bilirubin (CB) [water-soluble]
│
▼
CB excreted into bile → Intestine → Urobilinogen → Stercobilin (feces, brown color)
│
└─ Reabsorbed → Kidney → Urobilin (urine)
JAUNDICE MECHANISMS IN VIRAL HEPATITIS:
│
├──► HEPATOCELLULAR JAUNDICE (primary mechanism in viral hepatitis)
│ ↑UCB + ↑CB (both types elevated)
│ Hepatocyte damage → Impaired uptake, conjugation, AND excretion
│ → Conjugated bilirubin regurgitates into blood
│ → Dark urine (bilirubinuria), pale stools, jaundice
│
├──► CHOLESTATIC COMPONENT
│ Intrahepatic cholestasis due to canalicular damage
│ → Bile cannot flow → Back-pressure → CB enters blood
│
└──► Classification of Jaundice (for exam):
Pre-hepatic: ↑UCB only (hemolysis, Gilbert's)
Hepatic: ↑UCB + ↑CB (hepatitis, cirrhosis)
Post-hepatic: ↑CB only (bile duct obstruction, gallstones)
```
---
## 5. CLINICAL FEATURES
### 5.1 Phases of Acute Viral Hepatitis
```
Phase 1: PRODROMAL / PRE-ICTERIC PHASE (1–2 weeks)
────────────────────────────────────────────────
• Flu-like symptoms: fever (low-grade), malaise, fatigue
• Anorexia, nausea, vomiting
• Right upper quadrant (RUQ) discomfort / hepatic tenderness
• Arthralgias, myalgias
• Headache, photophobia
• Dark urine (bilirubinuria) — appears BEFORE jaundice
Phase 2: ICTERIC PHASE (2–6 weeks)
────────────────────────────────────────────────
• Jaundice — yellow skin, scleral icterus
• Pruritus (bile salt deposition in skin)
• Pale/clay-colored stools (acholic stools)
• Dark urine persists
• Hepatomegaly (tender), splenomegaly (in ~20%)
• Often: prodromal symptoms improve once jaundice appears
• Weight loss
Phase 3: CONVALESCENT / RECOVERY PHASE (weeks–months)
────────────────────────────────────────────────
• Jaundice fades
• Appetite returns
• Energy improves
• LFTs normalize
• Most patients with HAV/HBV (adults) recover fully
```
### 5.2 Symptoms by Hepatitis Type
| Feature | HAV | HBV | HCV | HDV | HEV |
|---------|-----|-----|-----|-----|-----|
| Acute illness severity | Mild–moderate | Variable | Mild (80% asymptomatic) | Severe | Mild (severe in pregnancy) |
| Jaundice in acute phase | Common | ~30% adults | <20% | Yes | Common |
| Chronic liver disease | No | Yes (5–10%) | Yes (55–85%) | Yes (high) | No |
| Fulminant hepatitis | Rare (<0.5%) | Rare (1%) | Very rare | High (co-infect 5%, superinfect 20%) | Rare (20% in pregnancy) |
### 5.3 Signs on Examination
- Jaundice (skin + sclera)
- Hepatomegaly — tender, smooth, enlarged liver
- Splenomegaly
- Lymphadenopathy (cervical)
- Spider angiomas, palmar erythema (in chronic disease)
- Asterixis, encephalopathy (in fulminant/advanced disease)
- Ascites, caput medusae (portal hypertension — late stage)
---
## 6. DIAGNOSIS
### 6.1 Laboratory Tests
**Liver Function Tests (LFTs):**
| Test | Finding in Acute Viral Hepatitis | Significance |
|------|----------------------------------|--------------|
| ALT (SGPT) | ↑↑↑ (markedly elevated, often >10× ULN) | Hepatocellular damage; most sensitive |
| AST (SGOT) | ↑↑↑ (elevated, slightly less than ALT) | Hepatocellular damage |
| ALT:AST ratio | >1 in viral hepatitis | (Alcoholic hepatitis: AST:ALT >2) |
| Serum Bilirubin | ↑ (total, direct + indirect) | Impaired conjugation/excretion |
| Alkaline Phosphatase | Mildly elevated | Cholestatic component |
| GGT | Mildly elevated | Hepatocellular/cholestatic marker |
| Serum Albumin | Decreased (in severe/chronic disease) | Impaired protein synthesis |
| Prothrombin Time (PT/INR) | Prolonged (in severe disease) | Impaired clotting factor synthesis |
**CBC:**
- Leukopenia with relative lymphocytosis (typical viral pattern)
- Atypical lymphocytes may be seen (EBV-related hepatitis)
**Urinalysis:**
- Bilirubinuria (dark urine) — conjugated bilirubin in urine
- Urobilinogens initially elevated, then absent in cholestasis
### 6.2 Serological Diagnosis
| Hepatitis Type | Marker | Interpretation |
|---------------|--------|----------------|
| **HAV** | Anti-HAV IgM | Active/recent infection |
| | Anti-HAV IgG | Past infection or vaccination (immunity) |
| **HBV** | HBsAg | Active infection (acute or chronic) |
| | Anti-HBs | Recovery or vaccination |
| | HBeAg | High infectivity, active replication |
| | Anti-HBe | Declining infectivity |
| | HBcAg | Found only in liver tissue |
| | Anti-HBc IgM | Acute infection |
| | Anti-HBc IgG | Past or chronic infection (window period marker) |
| | HBV DNA | Confirms active viral replication; monitors treatment |
| **HCV** | Anti-HCV | Exposure (acute or chronic; does NOT confirm active infection) |
| | HCV RNA (PCR) | Active viral replication; gold standard for diagnosis |
| | HCV genotype | Guides treatment duration and regimen |
| **HDV** | Anti-HDV IgM/IgG | HDV infection (requires HBsAg+) |
| | HDV RNA | Active infection |
| **HEV** | Anti-HEV IgM | Acute HEV infection |
| | Anti-HEV IgG | Past infection |
### 6.3 Imaging
- **Ultrasound (USG) abdomen** — First-line imaging; shows hepatomegaly, echogenicity changes, splenomegaly, ascites, bile duct dilation (to rule out obstructive jaundice)
- **Transient elastography (FibroScan)** — Non-invasive measure of liver stiffness/fibrosis in chronic disease
- **CT/MRI** — Rule out HCC, assess portal hypertension
### 6.4 Liver Biopsy
- Not routinely needed for acute viral hepatitis
- Indicated in: staging of chronic hepatitis, when diagnosis is uncertain
- Findings: lobular inflammation, hepatocyte necrosis (ballooning degeneration), Kupffer cell hyperplasia, portal infiltrates (lymphocytes)
---
## 7. TREATMENT GOALS
| Goal | Details |
|------|---------|
| **Acute Hepatitis A/E** | Symptomatic relief; prevent complications; avoid hepatotoxic drugs |
| **Chronic HBV** | Suppress HBV DNA to undetectable; HBeAg seroconversion; normalize ALT; prevent progression to cirrhosis and HCC |
| **Chronic HCV** | Achieve Sustained Virologic Response (SVR = undetectable HCV RNA 12 weeks after completing treatment) — functional cure |
| **General** | Prevent transmission; manage complications (ascites, encephalopathy); support liver regeneration |
| **Long-term** | Reduce risk of cirrhosis, liver failure, HCC; reduce need for liver transplantation |
**SVR (Sustained Virologic Response):** Defined as undetectable HCV RNA 12 weeks after end of treatment. SVR is considered a functional cure (~99% of patients who achieve SVR remain HCV-free long-term).
---
## 8. NON-PHARMACOLOGICAL TREATMENT
### 8.1 Rest and Activity
- Bed rest during symptomatic acute phase (not absolute)
- Gradual return to normal activity as symptoms resolve
- Avoid strenuous exercise until ALT normalizes
### 8.2 Diet and Nutrition
- **High-calorie, high-carbohydrate diet** — to support hepatocyte regeneration
- **Adequate protein** (white meat preferred: chicken, turkey, fish) — unless hepatic encephalopathy (protein restriction then required)
- **Low-fat diet** — fat intolerance common due to reduced bile secretion
- **Low-sodium diet** (1.5 g/day) if ascites or edema present
- **Fluid restriction** (1.5 L/day) if hyponatremia
- **Small, frequent meals** (nausea management)
- **Avoid alcohol completely** — even small amounts worsen hepatocellular damage
### 8.3 Medications to Avoid
- Hepatotoxic drugs (paracetamol in large doses, NSAIDs, antituberculous drugs without monitoring)
- Sedatives and hypnotics (impaired hepatic metabolism; may precipitate encephalopathy)
- Drugs requiring hepatic metabolism in severe liver disease
### 8.4 Hydration
- Ensure adequate oral hydration (IV fluids if vomiting is severe)
### 8.5 Isolation Precautions
- **HAV/HEV:** Enteric precautions (hand hygiene, food safety)
- **HBV/HCV/HDV:** Universal blood/body fluid precautions
### 8.6 Education and Counseling
- Transmission prevention (safe sex, no needle sharing)
- Importance of vaccination (HAV, HBV) for contacts
- Regular monitoring (follow-up LFTs, HBV DNA, HCV RNA)
- Avoidance of alcohol and hepatotoxic substances
### 8.7 Vaccination of Contacts
- HAV vaccine and/or immunoglobulin for close contacts
- HBV vaccine + HBIg for neonates of HBsAg+ mothers (within 12 hours of birth)
---
## 9. PHARMACOLOGICAL TREATMENT
---
### SECTION A: HEPATITIS B — ANTIVIRAL DRUGS
#### Drug Group 1: Nucleoside/Nucleotide Analogues (NAs)
**Short Introduction:**
NAs are the backbone of chronic HBV therapy. They are oral agents that mimic natural nucleosides/nucleotides and competitively inhibit the HBV reverse transcriptase (polymerase), blocking viral DNA synthesis. They suppress HBV replication but do not eradicate cccDNA (covalently closed circular DNA), so therapy is often long-term.
---
##### Drug 1: ENTECAVIR (ETV)
**Class:** Nucleoside analogue (guanosine analogue) — Preferred first-line agent
**MOA Flowchart:**
```
Entecavir (prodrug)
│
▼ Intracellular phosphorylation
Entecavir triphosphate (active form)
│
▼ Competitive inhibition of HBV DNA Polymerase/Reverse Transcriptase
│
├──► Inhibits priming of HBV DNA synthesis
├──► Inhibits reverse transcription of negative-strand DNA
└──► Inhibits synthesis of positive-strand HBV DNA
│
▼
Suppression of HBV replication → ↓ HBV DNA → ↓ Hepatic inflammation
```
| Parameter | Details |
|-----------|---------|
| **Dose** | Treatment-naive: **0.5 mg orally once daily** on empty stomach; Lamivudine-resistant: **1 mg orally once daily** |
| **Indication** | Chronic hepatitis B in adults and children ≥2 years with evidence of active viral replication |
| **ADR** | Headache, fatigue, upper abdominal pain, dizziness; **Lactic acidosis** (rare but serious); Exacerbation of hepatitis on discontinuation |
| **Drug Interactions** | Drugs that reduce renal function may increase ETV concentrations; nephrotoxic agents |
| **Contraindications** | Hypersensitivity; caution in renal impairment (dose adjustment required for CrCl <50 mL/min); avoid abrupt discontinuation in HBV patients |
| **Special Notes** | High barrier to resistance; preferred in cirrhosis; avoid in lamivudine-resistant patients (cross-resistance risk) without dose increase |
---
##### Drug 2: TENOFOVIR DISOPROXIL FUMARATE (TDF)
**Class:** Nucleotide analogue (adenosine monophosphate analogue) — Preferred first-line agent
**MOA Flowchart:**
```
Tenofovir Disoproxil Fumarate (prodrug — ester)
│
▼ Oral absorption (bioavailability ~25%; ↑ with high-fat meal)
Tenofovir (in blood)
│
▼ Intracellular phosphorylation by cellular kinases
Tenofovir diphosphate (active form)
│
▼ Competitive inhibition of HBV Reverse Transcriptase
(also inhibits HIV reverse transcriptase)
│
▼
Chain termination of viral DNA → Suppression of HBV/HIV replication
```
| Parameter | Details |
|-----------|---------|
| **Dose** | **300 mg orally once daily** (with or without food; food increases absorption) |
| **Indication** | Chronic HBV (adults and children ≥2 yrs); HIV infection (combined ART); HBV in HIV co-infected patients |
| **ADR** | Nausea, diarrhea, abdominal pain; **Nephrotoxicity** (proximal tubular dysfunction, Fanconi syndrome); Osteomalacia/decreased bone density; **Lactic acidosis** (rare but serious) |
| **Drug Interactions** | Avoid/monitor with other nephrotoxic drugs (NSAIDs, aminoglycosides); atazanavir + ritonavir may increase TDF levels; ↑ didanosine levels (avoid coadministration) |
| **Contraindications** | Severe renal impairment (CrCl <15 mL/min) — dose adjustment needed; osteoporosis risk requires monitoring; not preferred in patients with bone/renal disease (use TAF instead) |
---
##### Drug 3: TENOFOVIR ALAFENAMIDE FUMARATE (TAF)
**Class:** Nucleotide analogue — Newer prodrug of tenofovir; Preferred over TDF for renal/bone disease
**MOA Flowchart:**
```
TAF (prodrug — phosphonoamidate prodrug)
│
▼ Greater intracellular delivery to hepatocytes
Tenofovir diphosphate (active) — same as TDF
│
▼ Inhibition of HBV Reverse Transcriptase → Chain termination
│
(10× lower plasma tenofovir concentrations than TDF → ↓ renal/bone toxicity)
```
| Parameter | Details |
|-----------|---------|
| **Dose** | **25 mg orally once daily** |
| **Indication** | Chronic HBV in adults; preferred in patients with renal impairment or osteoporosis |
| **ADR** | Nausea, abdominal pain, diarrhea, fatigue; less nephrotoxicity and bone effects compared to TDF; weight gain (more than TDF) |
| **Drug Interactions** | Similar to TDF; rifampin/inducers decrease TAF levels; not for use with other TAF-containing products |
| **Contraindications** | Severe hepatic impairment (Child-Pugh C); abrupt discontinuation may cause hepatitis flare |
---
##### Drug 4: LAMIVUDINE (3TC)
**Class:** Nucleoside analogue (cytidine analogue) — Non-preferred (low barrier to resistance)
**MOA Flowchart:**
```
Lamivudine
│
▼ Intracellular phosphorylation → Lamivudine triphosphate
│
▼ Competitive inhibition of HBV reverse transcriptase
(also inhibits HIV reverse transcriptase)
│
▼ Chain termination → Suppression of HBV replication
(BUT: high rate of resistance mutation YMDD at 24% by year 1, ~70% by year 5)
```
| Parameter | Details |
|-----------|---------|
| **Dose** | **100 mg orally once daily** (HBV); 150 mg BD or 300 mg OD for HIV |
| **Indication** | Chronic HBV (no longer preferred — low resistance barrier); HIV; HBV/HIV co-infection (combined ART) |
| **ADR** | Headache, nausea, diarrhea, dizziness, myalgia; pancreatitis; lactic acidosis |
| **Drug Interactions** | Co-trimoxazole increases lamivudine levels; avoid drugs that cause pancreatitis |
| **Contraindications** | Monotherapy in HBV/HIV co-infected patients (select resistant HIV strains); not recommended as preferred first-line HBV agent |
---
##### Drug 5: ADEFOVIR DIPIVOXIL
**Class:** Nucleotide analogue (adenine analogue) — Third-line agent
| Parameter | Details |
|-----------|---------|
| **Dose** | **10 mg orally once daily** |
| **Indication** | Chronic HBV (especially 3TC-resistant); third-line agent |
| **ADR** | Renal dysfunction (dose-dependent; nephrotoxic at >10 mg/day), Fanconi syndrome, lactic acidosis |
| **Drug Interactions** | Ibuprofen increases adefovir plasma levels (increase AUC); monitor with nephrotoxic agents |
| **Contraindications** | Renal impairment requires dose adjustment; doses >10 mg/day avoid (nephrotoxic) |
---
#### Drug Group 2: Interferons
**Short Introduction:**
Interferons are endogenous cytokines with antiviral and immunomodulatory properties. Pegylated interferon alfa-2a (PEG-IFN-α-2a) is the injectable form used for HBV and HCV. The advantage over NAs is a finite treatment duration and higher HBeAg seroconversion rates; the disadvantage is significant side effects and parenteral administration.
---
##### Drug 6: PEGYLATED INTERFERON ALFA-2a (PEG-IFN-α-2a)
**Class:** Immunomodulator — Pegylated interferon
**MOA Flowchart:**
```
PEG-IFN-α-2a (subcutaneous injection)
│
▼ Binds to interferon receptor on hepatocytes
│
▼ Activates JAK-STAT signalling pathway
│
▼ Upregulates Interferon-Stimulated Genes (ISGs)
│
├──► Inhibits viral replication (direct antiviral)
│ — Activation of ribonuclease L → RNA degradation
│ — Activation of protein kinase R → Inhibits viral protein synthesis
│
└──► Immunomodulation
— ↑ NK cell activity
— ↑ CD8+ T lymphocyte activity
— ↑ MHC class I expression on hepatocytes
│
▼
↓ HBV/HCV replication + Enhanced immune clearance of infected hepatocytes
```
| Parameter | Details |
|-----------|---------|
| **Dose (HBV)** | **180 mcg SC once weekly × 48 weeks** |
| **Dose (HCV)** | 180 mcg SC once weekly (combination with ribavirin; now largely replaced by DAAs) |
| **Indication** | Chronic HBV (preferred for patients who want finite therapy; younger patients without cirrhosis); HCV (older therapy, now largely replaced) |
| **ADR** | **Flu-like syndrome** (fever, chills, myalgia — especially initial doses); **Fatigue, depression, suicidal ideation**; Myelosuppression (neutropenia, thrombocytopenia); Alopecia; Thyroid dysfunction; Autoimmune flares; Injection site reactions; Irritability, insomnia |
| **Drug Interactions** | Theophylline toxicity (↑ levels via CYP1A2 inhibition); myelosuppressive agents increase bone marrow toxicity; immunosuppressants |
| **Contraindications** | **Decompensated cirrhosis (Child-Pugh >6)** — risk of hepatic decompensation; Autoimmune hepatitis; Severe psychiatric illness (depression/suicidal ideation); Uncontrolled seizures; Bone marrow suppression; Severe cardiac/pulmonary disease; Pregnancy |
---
### SECTION B: HEPATITIS C — DIRECT-ACTING ANTIVIRALS (DAAs)
**Short Introduction:**
DAAs target specific non-structural (NS) proteins of HCV that are essential for viral replication. The advent of DAAs revolutionized HCV treatment — cure rates (SVR) exceed 95%, treatment duration is 8–12 weeks (oral), and the drugs are generally well tolerated. Current preferred regimens include pangenotypic combinations.
#### HCV Replication Targets:
```
HCV RNA
│
▼ Translation
Polyprotein
│
▼ Cleaved by:
├── NS3/4A Protease → processes viral polyprotein
├── NS5A → replication complex formation
└── NS5B RNA Polymerase → viral RNA replication
DAA Classes target:
NS3/4A Protease Inhibitors (-previr) ──► NS3/4A
NS5A Inhibitors (-asvir) ──► NS5A
NS5B Nucleotide Inhibitors (sofosbuvir) ──► NS5B
```
---
##### Drug 7: SOFOSBUVIR (SOF) — NS5B Inhibitor
**Class:** Nucleotide analogue (NS5B RNA Polymerase inhibitor)
**MOA Flowchart:**
```
Sofosbuvir (prodrug)
│
▼ Absorbed in intestine → Rapid conversion to GS-331007
│
▼ Taken up by hepatocytes → Phosphorylation by cellular kinases
│
▼ Active form: GS-461203 (uridine triphosphate analogue)
│
▼ Incorporated by HCV NS5B RNA Polymerase
into elongating RNA strand
│
▼ CHAIN TERMINATION → HCV RNA synthesis blocked
│
▼ ↓ HCV RNA → SVR > 95%
```
| Parameter | Details |
|-----------|---------|
| **Dose** | **400 mg orally once daily** (with food); part of combination: SOF/VEL, SOF/LDV, SOF/VEL/VOX |
| **Indication** | Chronic HCV (all genotypes when combined with NS5A inhibitor); used in combinations only |
| **ADR** | Fatigue, headache, asthenia, nausea; when combined with ribavirin: anemia, rash |
| **Drug Interactions** | P-gp inducers (rifampin, carbamazepine, St. John's wort, phenytoin) → ↓ SOF levels (contraindicated); amiodarone + SOF → serious bradycardia (contraindicated); coadministration with tipranavir/ritonavir also contraindicated |
| **Contraindications** | Coadministration with amiodarone (fatal bradycardia); P-gp inducers; severe renal impairment with velpatasvir combination (CrCl <30 mL/min for SOF/VEL/VOX); pregnancy with ribavirin-containing regimens |
---
##### Drug 8: LEDIPASVIR (LDV) — NS5A Inhibitor [Combined as SOF/LDV — Harvoni]
**Class:** NS5A Inhibitor
**MOA Flowchart:**
```
Ledipasvir
│
▼ Binds NS5A protein of HCV
│
▼ Inhibits NS5A phosphorylation and function
│
├──► Disrupts viral replication complex formation
└──► Inhibits viral assembly and release
│
▼ Combined with Sofosbuvir (Harvoni: SOF 400mg + LDV 90mg)
→ Dual mechanism → ↑ SVR rates (>95%) for genotypes 1, 4, 5, 6
```
| Parameter | Details |
|-----------|---------|
| **Dose (as Harvoni)** | **SOF 400 mg/LDV 90 mg once daily × 8–12 weeks** (genotype 1 treatment-naive non-cirrhotic) |
| **Indication** | HCV genotypes 1, 4, 5, 6 |
| **ADR** | Fatigue, headache, nausea, insomnia, asthenia |
| **Drug Interactions** | Antacids/H2-blockers may ↓ LDV absorption (take with food; space from antacids); rifampin, carbamazepine, St. John's wort reduce levels; rosuvastatin ↑ levels (avoid); tenofovir ↑ levels with strong P-gp inhibitors |
| **Contraindications** | Coadministration with strong P-gp inducers; hepatitis C with decompensated cirrhosis may need modified regimens + ribavirin |
---
##### Drug 9: GLECAPREVIR/PIBRENTASVIR (GLE/PIB) — Pangenotypic Combination [Mavyret]
**Class:** NS3/4A Protease Inhibitor (Glecaprevir) + NS5A Inhibitor (Pibrentasvir) — Pangenotypic
**MOA Flowchart:**
```
GLECAPREVIR (NS3/4A Protease Inhibitor) PIBRENTASVIR (NS5A Inhibitor)
│ │
▼ ▼
Binds NS3/4A serine protease Binds NS5A protein
│ │
▼ ▼
Inhibits HCV polyprotein cleavage Disrupts replication complex
(prevents release of functional + inhibits viral assembly
viral proteins NS4A, NS4B, NS5A, NS5B) │
│ │
└───────────────────┬───────────────────────┘
▼
Dual NS3/4A + NS5A inhibition
│
▼
Pan-genotypic HCV suppression → SVR >95%
```
| Parameter | Details |
|-----------|---------|
| **Dose** | **GLE 300 mg/PIB 120 mg once daily** (3 tablets together with food) |
| **Duration** | Treatment-naive, no cirrhosis: **8 weeks** (all genotypes); Compensated cirrhosis: 8–12 weeks; DAA-experienced: 12–16 weeks |
| **Indication** | Chronic HCV genotypes 1–6 (pangenotypic); preferred for patients with renal impairment (no dose adjustment needed) |
| **ADR** | Headache, fatigue, nausea; Pruritus; elevated bilirubin (indirect, not hepatotoxic) |
| **Drug Interactions** | P-gp inducers (rifampin, carbamazepine) → ↓ drug levels (contraindicated); Statins (inhibit OATP1B1/1B3) → ↑ statin levels → myopathy risk (avoid lovastatin, simvastatin; use with caution with rosuvastatin); Dabigatran/digoxin (P-gp substrates) → ↑ levels; Cyclosporine → ↑ GLE/PIB levels (contraindicated if cyclosporine dose >100 mg/day); Ethinyl estradiol-containing contraceptives → risk of ALT elevation |
| **Contraindications** | Decompensated cirrhosis (Child-Pugh B/C); coadministration with rifampin, strong P-gp inducers; severe hepatic impairment |
---
##### Drug 10: SOFOSBUVIR/VELPATASVIR (SOF/VEL) — Pangenotypic [Epclusa]
**Class:** NS5B Inhibitor (Sofosbuvir) + NS5A Inhibitor (Velpatasvir) — Pangenotypic
| Parameter | Details |
|-----------|---------|
| **Dose** | **SOF 400 mg/VEL 100 mg once daily × 12 weeks** (all genotypes, with or without compensated cirrhosis); +Ribavirin for decompensated cirrhosis |
| **Indication** | Chronic HCV genotypes 1–6 (pangenotypic); decompensated cirrhosis (with ribavirin) |
| **ADR** | Headache, fatigue, nausea, insomnia, asthenia |
| **Drug Interactions** | P-gp/CYP inducers (rifampin, St. John's wort, carbamazepine) contraindicated; antacids → ↓ VEL absorption (space 4 hours); efavirenz → ↓ VEL levels (avoid); amiodarone (avoid); tenofovir monitoring required |
| **Contraindications** | Coadministration with amiodarone; P-gp/CYP inducers; Child-Pugh C without ribavirin combination |
---
##### Drug 11: RIBAVIRIN (RBV)
**Class:** Nucleoside analogue — used in combination with DAAs or interferons (never as monotherapy)
**Short Introduction:**
Ribavirin is a synthetic guanosine nucleoside analogue with broad-spectrum antiviral activity. Although its exact mechanism in HCV is not fully defined, it enhances SVR rates when added to interferon or certain DAA regimens, particularly in decompensated cirrhosis.
**MOA Flowchart:**
```
Ribavirin
│
▼ Intracellular phosphorylation → Ribavirin triphosphate
│
├──► Inhibits inosine monophosphate dehydrogenase (IMPDH)
│ → ↓ GTP pool → ↓ Viral RNA synthesis
│
├──► RNA mutagenesis (error catastrophe)
│ → Incorporates into viral RNA → Lethal mutations
│
└──► Immunomodulation: Shifts Th2 to Th1 response
→ Enhanced cellular immunity against HCV
```
| Parameter | Details |
|-----------|---------|
| **Dose** | Weight-based: **<75 kg: 1000 mg/day; ≥75 kg: 1200 mg/day** orally in 2 divided doses with food |
| **Indication** | Combined with SOF/VEL for decompensated cirrhosis; with PEG-IFN (older regimens); retreatment of certain DAA failures |
| **ADR** | **Hemolytic anemia** (most significant — dose-limiting); Teratogenicity; Fatigue, depression, insomnia; Rash, pruritus; Cough (inhaled form) |
| **Drug Interactions** | **Didanosine** → ↑ risk of pancreatitis, lactic acidosis (contraindicated); Zidovudine → ↑ anemia risk (avoid); azathioprine — serious pancytopenia reported |
| **Contraindications** | **Pregnancy and breastfeeding** (Category X — teratogenic); hemoglobin <10 g/dL; severe renal impairment (CrCl <50 mL/min); hemolytic anemia; significant cardiac disease (anemia-related risk) |
---
### SECTION C: SYMPTOMATIC / SUPPORTIVE DRUGS
#### Drug 12: URSODEOXYCHOLIC ACID (UDCA)
**Class:** Bile acid — Hepatoprotective agent
| Parameter | Details |
|-----------|---------|
| **Dose** | 13–15 mg/kg/day in 2–3 divided doses |
| **Indication** | Cholestatic liver disease; pruritus in jaundice; intrahepatic cholestasis of pregnancy |
| **MOA** | Replaces toxic hydrophobic bile acids with hydrophilic UDCA → Stabilizes hepatocyte membranes → Cytoprotective; stimulates bile flow; immunomodulatory |
| **ADR** | Diarrhea, nausea, pruritus worsening initially |
| **Contraindications** | Acute cholecystitis; biliary obstruction; calcified gallstones |
#### Drug 13: SILYMARIN (Milk Thistle / Silybum marianum)
| Parameter | Details |
|-----------|---------|
| **Dose** | 140 mg TDS (as standardized extract) |
| **Indication** | Adjunct hepatoprotection in hepatitis; supportive therapy |
| **MOA** | Antioxidant (free radical scavenging); inhibits lipid peroxidation; stabilizes hepatocyte membranes; anti-fibrotic properties |
| **ADR** | GI disturbances (mild), allergic reactions (rare) |
| **Contraindications** | Hypersensitivity to Asteraceae family |
#### Drug 14: ANTIPRURITIC AGENTS (for jaundice-related pruritus)
| Drug | Dose | MOA | Notes |
|------|------|-----|-------|
| Cholestyramine | 4–8 g BD–QID | Bile acid sequestrant → ↓ bile acid reabsorption | First-line for cholestatic pruritus |
| Rifampicin | 150–300 mg/day | Pregnane X receptor agonist → ↑ bile acid metabolism | Second-line |
| Naltrexone | 50 mg/day | Opioid antagonist → blocks opioid-mediated pruritus | Second-line |
| Antihistamines (e.g., hydroxyzine) | 25 mg OD–TDS | H1 antagonist → sedative; limited efficacy for bile salt pruritus | Adjunct |
---
## 10. PHARMACOLOGICAL TREATMENT SUMMARY CHART
### Hepatitis B — Drug Summary
| Drug | Class | Dose | Key ADR | Key Drug Interactions | Contraindications |
|------|-------|------|---------|----------------------|-------------------|
| **Entecavir** | NA — Guanosine analogue | 0.5 mg OD (naive); 1 mg OD (LAM-resistant) | Lactic acidosis, headache, fatigue | Nephrotoxic drugs | CrCl <50 (dose adjust); no abrupt stop |
| **Tenofovir DF (TDF)** | NA — Adenosine nucleotide | 300 mg OD | Nephrotoxicity, Fanconi syndrome, osteomalacia, lactic acidosis | NSAIDs, atazanavir/r, ddI | Renal impairment (adjust); osteoporosis (prefer TAF) |
| **Tenofovir AF (TAF)** | NA — Adenosine nucleotide (prodrug) | 25 mg OD | Nausea, weight gain; less nephrotox than TDF | Rifampin ↓ levels | Severe hepatic impairment; no abrupt stop |
| **Lamivudine** | NA — Cytidine analogue | 100 mg OD (HBV) | High resistance (YMDD mutation), pancreatitis, LA | Co-trimoxazole ↑ levels | HBV/HIV mono (select HIV-R); not preferred 1st-line |
| **Adefovir** | NA — Adenine nucleotide | 10 mg OD | Nephrotoxicity, Fanconi | Ibuprofen ↑ levels | Renal impairment; doses >10 mg nephrotoxic |
| **PEG-IFN-α-2a** | Immunomodulator — Interferon | 180 mcg SC weekly × 48 wks | Flu-like, depression, neutropenia, alopecia, thyroid dysfunction | Theophylline ↑ levels; myelosuppressants | Decompensated cirrhosis, autoimmune hep, severe psych, pregnancy |
### Hepatitis C — DAA Summary
| Drug | Class | Target | Dose | Duration | Genotype | Key ADR | Key Contraindications |
|------|-------|--------|------|----------|----------|---------|----------------------|
| **SOF/LDV (Harvoni)** | NS5B + NS5A | NS5B, NS5A | 400/90 mg OD | 8–12 weeks | 1, 4, 5, 6 | Fatigue, headache | Amiodarone, rifampin, P-gp inducers |
| **SOF/VEL (Epclusa)** | NS5B + NS5A | NS5B, NS5A | 400/100 mg OD | 12 weeks | 1–6 | Headache, fatigue, nausea | Amiodarone, P-gp inducers, efavirenz |
| **GLE/PIB (Mavyret)** | NS3/4A + NS5A | NS3/4A, NS5A | 300/120 mg OD | 8 weeks (naive, no cirrhosis) | 1–6 | Headache, pruritus | Decompensated cirrhosis, rifampin, cyclosporine >100 mg |
| **SOF/VEL/VOX (Vosevi)** | NS5B+NS5A+NS3/4A | Triple target | 400/100/100 mg OD | 12 weeks | 1–6 (retreatment) | Headache, fatigue, nausea | P-gp inducers, amiodarone |
| **Ribavirin** | Nucleoside analogue | IMPDH, viral mutagenesis | Weight-based (1000–1200 mg/day) | With DAA/IFN | Adjunct | Hemolytic anemia, teratogenicity | Pregnancy, anemia, severe renal impairment |
---
## 11. MOA COMPARISON — FLOWCHART OVERVIEW
```
HEPATITIS B TREATMENT TARGETS:
HBV Lifecycle
│
Viral entry ──► Uncoating ──► Nuclear transport
│
cccDNA (persistent reservoir)
│
┌─────────┴─────────┐
pgRNA synthesis mRNA synthesis
│
Reverse Transcriptase (RT)
←──── INHIBITED BY NAs ────→
(Entecavir, TDF, TAF, LAM, Adefovir)
│
HBV DNA synthesis
│
Virion assembly & release
←── PEG-IFN: Immune-mediated clearance
HEPATITIS C TREATMENT TARGETS:
HCV RNA → Translation → Polyprotein
│
NS3/4A Protease cleavage
←── Inhibited by Glecaprevir ──
│
Functional viral proteins
│
NS5A: Replication complex
←── Inhibited by Ledipasvir,
Velpatasvir, Pibrentasvir ──
│
NS5B RNA Polymerase: RNA copying
←── Inhibited by Sofosbuvir ──
│
New HCV RNA genomes
```
---
## 12. COMPLICATIONS OF VIRAL HEPATITIS
| Complication | Associated Virus | Details |
|-------------|-----------------|---------|
| Cirrhosis | HBV, HCV, HDV | Progressive fibrosis; portal hypertension |
| Hepatocellular Carcinoma (HCC) | HBV, HCV | Major cause; screening q6 months (AFP + USG) |
| Fulminant Hepatic Failure | HAV, HBV, HDV co-infection, HEV (pregnancy) | Encephalopathy, coagulopathy |
| Aplastic anemia | HAV, HBV | Rare |
| Cryoglobulinemia | HCV | Vasculitis, arthritis, glomerulonephritis |
| Glomerulonephritis | HBV (membranous), HCV | Nephrotic syndrome |
| Portal Hypertension | Chronic HBV/HCV/HDV | Varices, ascites, splenomegaly |
---
## 13. PREVENTION
| Hepatitis | Prevention Strategies |
|-----------|----------------------|
| **HAV** | Vaccination (2-dose series); hand hygiene; safe food/water; post-exposure IG within 2 weeks |
| **HBV** | Vaccination (3-dose series: 0, 1, 6 months); HBIg + vaccine for neonates of HBsAg+ mothers; safe sex; no needle sharing; blood screening |
| **HCV** | No vaccine; harm reduction (needle programs, safe injection); blood screening; universal precautions |
| **HDV** | HBV vaccination prevents HDV (requires HBV co-infection) |
| **HEV** | Vaccine (Hecolin® — available in China); safe water/food; hand hygiene |
---
## 14. ROLE OF THE PHARMACIST
1. **Medication counseling** — Explain importance of adherence (especially for HBV — abrupt discontinuation causes hepatitis flares)
2. **Monitoring ADRs** — Renal function (TDF/adefovir), CBC (RBV/PEG-IFN), LFTs (all antivirals), mental health (PEG-IFN)
3. **Drug interaction screening** — P-gp inducers with DAAs; nephrotoxic combos with NAs; ribavirin + didanosine
4. **Patient education** — Alcohol avoidance; avoid hepatotoxic OTC drugs; importance of follow-up
5. **Vaccination recommendations** — Encourage HAV/HBV vaccination of susceptible contacts
6. **Pregnancy counseling** — Ribavirin is absolutely contraindicated; most DAAs not established in pregnancy
7. **Ensure treatment completion** — Emphasize SVR concept; non-adherence leads to virologic failure
---
## 15. QUICK REVIEW — MNEMONICS
**Hepatitis transmission routes — "B, C, D: Blood; A, E: Alimentary"**
- Blood-borne: HBV, HCV, HDV
- Alimentary (fecal-oral): HAV, HEV
**HBV first-line agents:** "ETP" — **E**ntecavir, **T**enofovir (TDF/TAF), **P**eg-IFN
**DAA classes in HCV — "3 + 5A + 5B":**
- NS**3**/4A Protease inhibitors: Glecaprevir (-**previr**)
- NS**5A** inhibitors: Ledipasvir, Velpatasvir, Pibrentasvir (-**asvir**)
- NS**5B** inhibitors: Sofosbuvir (-**buvir**)
**Ribavirin main ADR:** "**HATE**" — **H**emolytic anemia, **A**emia, **T**eratogenic, **E**xcluded in pregnancy
**Jaundice types:**
- Pre-hepatic → **↑ Unconjugated** bilirubin; normal LFTs
- Hepatic → **↑ Both** (unconjugated + conjugated); ↑ ALT/AST
- Post-hepatic → **↑ Conjugated** bilirubin; ↑ ALP/GGT
---
*Sources: Katzung's Basic and Clinical Pharmacology 16th Ed.; Goldman-Cecil Medicine; Harrison's Principles of Internal Medicine 22nd Ed.; pharmdguru.com/viral-hepatitis-including-jaundice/; PMC8218370 (Viral Hepatitis Management Update); Medscape Hepatitis B Treatment.*
Reading File
Writing File
~/viral-hepatitis-notes/create_notes.py
from docx import Document
from docx.shared import Pt, Inches, RGBColor, Cm
from docx.enum.text import WD_ALIGN_PARAGRAPH
from docx.oxml.ns import qn
from docx.oxml import OxmlElement
import copy
doc = Document()
# Page margins
from docx.oxml.ns import nsmap
sections = doc.sections
for section in sections:
section.top_margin = Cm(1.8)
section.bottom_margin = Cm(1.8)
section.left_margin = Cm(2.2)
section.right_margin = Cm(2.0)
# Color palette
DARK_BLUE = RGBColor(0x1A, 0x34, 0x6B)
MED_BLUE = RGBColor(0x1E, 0x6E, 0xBE)
TEAL = RGBColor(0x00, 0x7A, 0x87)
ORANGE = RGBColor(0xD9, 0x6A, 0x00)
DARK_GREEN = RGBColor(0x1B, 0x6B, 0x3A)
LIGHT_BG = RGBColor(0xF0, 0xF6, 0xFF)
RED = RGBColor(0xC0, 0x20, 0x20)
GREY = RGBColor(0x55, 0x55, 0x55)
WHITE = RGBColor(0xFF, 0xFF, 0xFF)
# Heading styles helper
def set_heading_style(para, level=1, color=DARK_BLUE):
run = para.runs[0] if para.runs else para.add_run(para.text)
run.font.color.rgb = color
run.font.bold = True
if level == 1:
run.font.size = Pt(16)
elif level == 2:
run.font.size = Pt(13)
elif level == 3:
run.font.size = Pt(11.5)
def shade_table_header(row, color_hex):
for cell in row.cells:
tc = cell._tc
tcPr = tc.get_or_add_tcPr()
shd = OxmlElement('w:shd')
shd.set(qn('w:fill'), color_hex)
shd.set(qn('w:val'), 'clear')
tcPr.append(shd)
def shade_cell(cell, color_hex):
tc = cell._tc
tcPr = tc.get_or_add_tcPr()
shd = OxmlElement('w:shd')
shd.set(qn('w:fill'), color_hex)
shd.set(qn('w:val'), 'clear')
tcPr.append(shd)
def add_colored_heading(doc, text, level=1, color=DARK_BLUE, size=15):
p = doc.add_paragraph()
p.paragraph_format.space_before = Pt(10)
p.paragraph_format.space_after = Pt(4)
run = p.add_run(text)
run.bold = True
run.font.color.rgb = color
run.font.size = Pt(size)
return p
def add_subheading(doc, text, color=MED_BLUE, size=12):
p = doc.add_paragraph()
p.paragraph_format.space_before = Pt(6)
p.paragraph_format.space_after = Pt(2)
run = p.add_run(text)
run.bold = True
run.font.color.rgb = color
run.font.size = Pt(size)
return p
def add_body(doc, text, bold=False, italic=False, color=None, size=10.5):
p = doc.add_paragraph()
p.paragraph_format.space_before = Pt(1)
p.paragraph_format.space_after = Pt(2)
run = p.add_run(text)
run.bold = bold
run.italic = italic
run.font.size = Pt(size)
if color:
run.font.color.rgb = color
return p
def add_bullet(doc, text, level=0, color=None):
p = doc.add_paragraph(style='List Bullet')
p.paragraph_format.space_before = Pt(1)
p.paragraph_format.space_after = Pt(1)
p.paragraph_format.left_indent = Inches(0.25 + level * 0.2)
run = p.add_run(text)
run.font.size = Pt(10.5)
if color:
run.font.color.rgb = color
return p
def add_code_block(doc, text, color=DARK_GREEN):
"""Simulate a flowchart/code block with a bordered paragraph."""
p = doc.add_paragraph()
p.paragraph_format.left_indent = Inches(0.3)
p.paragraph_format.right_indent = Inches(0.3)
p.paragraph_format.space_before = Pt(4)
p.paragraph_format.space_after = Pt(4)
# add light background shading
pPr = p._p.get_or_add_pPr()
shd = OxmlElement('w:shd')
shd.set(qn('w:fill'), 'E8F4E8')
shd.set(qn('w:val'), 'clear')
pPr.append(shd)
run = p.add_run(text)
run.font.size = Pt(9)
run.font.name = 'Courier New'
run.font.color.rgb = color
return p
def add_separator(doc):
p = doc.add_paragraph()
p.paragraph_format.space_before = Pt(2)
p.paragraph_format.space_after = Pt(2)
run = p.add_run("─" * 100)
run.font.size = Pt(7)
run.font.color.rgb = RGBColor(0xCC, 0xCC, 0xCC)
def make_table(doc, headers, rows, col_widths=None, header_color='1A346B'):
table = doc.add_table(rows=1+len(rows), cols=len(headers))
table.style = 'Table Grid'
# Header row
hdr = table.rows[0]
shade_table_header(hdr, header_color)
for i, h in enumerate(headers):
c = hdr.cells[i]
c.text = ''
run = c.paragraphs[0].add_run(h)
run.bold = True
run.font.color.rgb = WHITE
run.font.size = Pt(9.5)
c.paragraphs[0].alignment = WD_ALIGN_PARAGRAPH.CENTER
# Data rows
for ri, row_data in enumerate(rows):
row = table.rows[ri+1]
if ri % 2 == 0:
shade_table_header(row, 'F0F6FF')
for ci, cell_text in enumerate(row_data):
c = row.cells[ci]
c.text = ''
run = c.paragraphs[0].add_run(str(cell_text))
run.font.size = Pt(9)
# Set col widths
if col_widths:
for i, w in enumerate(col_widths):
for row in table.rows:
row.cells[i].width = Inches(w)
doc.add_paragraph() # spacing after table
# ========== TITLE PAGE ==========
title_p = doc.add_paragraph()
title_p.alignment = WD_ALIGN_PARAGRAPH.CENTER
title_p.paragraph_format.space_before = Pt(20)
run = title_p.add_run("VIRAL HEPATITIS INCLUDING JAUNDICE")
run.bold = True
run.font.size = Pt(20)
run.font.color.rgb = DARK_BLUE
sub_p = doc.add_paragraph()
sub_p.alignment = WD_ALIGN_PARAGRAPH.CENTER
run2 = sub_p.add_run("Therapeutics 3 — Comprehensive Study Notes")
run2.font.size = Pt(13)
run2.font.color.rgb = MED_BLUE
run2.bold = True
sub_p2 = doc.add_paragraph()
sub_p2.alignment = WD_ALIGN_PARAGRAPH.CENTER
run3 = sub_p2.add_run("Sources: Katzung Pharmacology 16e | Goldman-Cecil Medicine | Harrison's 22e | pharmdguru.com")
run3.font.size = Pt(9)
run3.font.color.rgb = GREY
run3.italic = True
doc.add_paragraph()
add_separator(doc)
doc.add_paragraph()
# ========== 1. INTRODUCTION ==========
add_colored_heading(doc, "1. INTRODUCTION", 1, DARK_BLUE, 14)
add_body(doc, "Viral hepatitis is inflammation of the liver caused by one of five hepatotropic viruses (HAV, HBV, HCV, HDV, HEV). It is a major global health burden — the WHO estimates over 354 million people worldwide live with chronic hepatitis B or C, causing approximately 1.1 million deaths annually from cirrhosis and hepatocellular carcinoma (HCC).")
add_body(doc, "Jaundice (icterus) is the yellow discoloration of the skin, sclera, and mucous membranes due to hyperbilirubinemia. It becomes clinically visible when serum bilirubin exceeds 2–3 mg/dL (normal: 0.2–1.2 mg/dL). Jaundice is a cardinal manifestation of viral hepatitis but may also result from pre-hepatic (hemolytic) or post-hepatic (obstructive) causes.")
# ========== 2. DEFINITION ==========
add_colored_heading(doc, "2. DEFINITION", 1, DARK_BLUE, 14)
def_rows = [
["Viral Hepatitis", "Inflammation of liver parenchyma caused by hepatotropic viruses (HAV, HBV, HCV, HDV, HEV), leading to hepatocellular injury, necrosis, and impaired liver function"],
["Acute Hepatitis", "Liver inflammation lasting <6 months; usually self-limiting (HAV, HEV, most adult HBV)"],
["Chronic Hepatitis", "Persistent hepatic inflammation >6 months; may progress to cirrhosis and HCC (HBV, HCV, HDV)"],
["Jaundice", "Yellow discoloration of skin/sclera due to bilirubin accumulation; serum bilirubin >2.5–3 mg/dL"],
["Icteric Phase", "Clinical phase of acute hepatitis when jaundice is clinically apparent (phase 2 of acute hepatitis)"],
["SVR", "Sustained Virologic Response — undetectable HCV RNA 12 weeks post-treatment = functional cure (>95% with DAAs)"],
["Fulminant Hepatitis", "Massive hepatic necrosis + encephalopathy developing within 8 weeks of symptom onset; may require liver transplant"],
]
make_table(doc, ["Term", "Definition"], def_rows, [1.8, 5.0], '1A346B')
# ========== 3. ETIOLOGY ==========
add_colored_heading(doc, "3. ETIOLOGY", 1, DARK_BLUE, 14)
add_subheading(doc, "3.1 Types of Viral Hepatitis — Comparison", MED_BLUE, 11.5)
etio_rows = [
["HAV", "Picornaviridae", "ssRNA(+)", "Fecal-oral", "2–6 wk", "None", "Yes"],
["HBV", "Hepadnaviridae", "Partial dsDNA", "Parenteral, sexual, vertical", "6 wk–6 mo", "5–10% (adults); 90% (neonates)", "Yes"],
["HCV", "Flaviviridae", "ssRNA(+)", "Parenteral (mainly)", "2 wk–6 mo", "55–85%", "No"],
["HDV", "Deltaviridae", "ssRNA(−)", "Parenteral (requires HBV)", "3–7 wk", "High (superinfection)", "Via HBV vaccine"],
["HEV", "Hepeviridae", "ssRNA(+)", "Fecal-oral", "2–9 wk", "None (except immunocomp.)", "Yes (limited countries)"],
]
make_table(doc, ["Type", "Family", "Genome", "Transmission", "Incubation", "Chronicity", "Vaccine"], etio_rows, [0.6, 1.3, 1.0, 1.6, 0.9, 1.5, 0.8], '1E6EBE')
add_subheading(doc, "3.2 Risk Factors", MED_BLUE, 11.5)
add_bullet(doc, "HAV/HEV (Fecal-Oral): Contaminated food/water; travel to endemic areas; poor sanitation; overcrowding")
add_bullet(doc, "HBV/HCV/HDV (Parenteral): IVDU; unprotected sex (esp. HBV); needlestick injuries; blood transfusions; vertical transmission (HBV neonate); tattooing with unsterilized equipment")
# ========== 4. PATHOPHYSIOLOGY ==========
add_colored_heading(doc, "4. PATHOPHYSIOLOGY", 1, DARK_BLUE, 14)
add_subheading(doc, "4.1 Pathophysiology of Viral Hepatitis — Flowchart", MED_BLUE, 11.5)
add_code_block(doc, """VIRAL ENTRY
├─ HAV/HEV: Ingestion → GI tract → Portal circulation → Hepatocytes
└─ HBV/HCV/HDV: Bloodborne → Systemic circulation → Hepatocytes
↓
VIRAL REPLICATION IN HEPATOCYTES
↓
Viral antigens expressed on hepatocyte surface
↓
IMMUNE RECOGNITION
├─ CD8+ Cytotoxic T Lymphocytes → Hepatocellular NECROSIS → ↑ ALT/AST
└─ CD4+ Helper T cells → Cytokine release (TNF-α, IFN-γ) → INFLAMMATION
↓
HEPATOCELLULAR INJURY
├─ ↓ Albumin, ↓ Clotting factors (↑ INR)
├─ ↓ Bilirubin conjugation/excretion → JAUNDICE
↓
OUTCOMES:
├─ RESOLUTION (HAV, HEV; most adult HBV)
├─ CHRONIC HEPATITIS (HBV 5–10%, HCV 55–85%) → Fibrosis → CIRRHOSIS → HCC/Portal Hypertension
└─ FULMINANT HEPATITIS (rare) → Acute Liver Failure → Death/Transplant""")
add_subheading(doc, "4.2 Pathophysiology of Jaundice — Flowchart", MED_BLUE, 11.5)
add_code_block(doc, """NORMAL BILIRUBIN METABOLISM:
Heme (RBC breakdown) → Biliverdin → Unconjugated Bilirubin (UCB, fat-soluble, albumin-bound)
↓ Hepatic uptake + Conjugation with glucuronic acid
Conjugated Bilirubin (CB, water-soluble)
↓ Excreted into bile → Intestine → Urobilinogen → Stercobilin (brown feces)
└─ Reabsorbed → Kidney → Urobilin (yellow urine)
JAUNDICE IN VIRAL HEPATITIS (Hepatocellular type):
Hepatocyte damage → Impaired UCB uptake + Impaired conjugation + Impaired CB excretion
↓
BOTH UCB and CB elevated in blood
↓
Clinical features: Yellow skin/sclera, Dark urine (bilirubinuria), Pale/clay stools, Pruritus
THREE TYPES OF JAUNDICE (for exams):
┌─────────────────┬──────────────────┬────────────────────────────┐
│ Pre-hepatic │ Hepatic │ Post-hepatic │
├─────────────────┼──────────────────┼────────────────────────────┤
│ ↑ Unconjugated │ ↑ UCB + ↑ CB │ ↑ Conjugated only │
│ Normal LFTs │ ↑ ALT/AST │ ↑ ALP/GGT │
│ Hemolysis │ Viral hepatitis │ Gallstones, pancreatic Ca │
└─────────────────┴──────────────────┴────────────────────────────┘""")
# ========== 5. CLINICAL FEATURES ==========
add_colored_heading(doc, "5. CLINICAL FEATURES", 1, DARK_BLUE, 14)
add_subheading(doc, "5.1 Phases of Acute Viral Hepatitis", MED_BLUE, 11.5)
phase_rows = [
["Phase 1: Prodromal\n(Pre-icteric)\n1–2 weeks", "• Flu-like: fever (low-grade), malaise, fatigue, anorexia\n• Nausea, vomiting\n• RUQ discomfort, hepatic tenderness\n• Arthralgias, myalgias, headache\n• Dark urine (bilirubinuria) — appears BEFORE jaundice"],
["Phase 2: Icteric\n2–6 weeks", "• Jaundice — yellow skin, scleral icterus\n• Pruritus (bile salt deposition in skin)\n• Pale/clay-colored stools (acholic stools)\n• Hepatomegaly (tender), splenomegaly (~20%)\n• Weight loss\n• Prodromal symptoms often improve once jaundice appears"],
["Phase 3: Convalescent\n(Recovery)\nWeeks–months", "• Jaundice fades gradually\n• Appetite and energy return\n• LFTs normalize\n• Most HAV/HBV (adults) recover completely\n• Chronic infection possible with HBV (5–10%), HCV (55–85%)"],
]
make_table(doc, ["Phase", "Features"], phase_rows, [1.6, 5.2], '007A87')
add_subheading(doc, "5.2 Signs on Examination", MED_BLUE, 11.5)
for sign in ["Jaundice — skin, scleral icterus", "Hepatomegaly — tender, smooth, enlarged liver", "Splenomegaly (20%)", "Lymphadenopathy (cervical)", "Spider angiomas, palmar erythema (chronic disease)", "Asterixis, encephalopathy (fulminant/advanced disease)", "Ascites, caput medusae (portal hypertension — late)"]:
add_bullet(doc, sign)
# ========== 6. DIAGNOSIS ==========
add_colored_heading(doc, "6. DIAGNOSIS", 1, DARK_BLUE, 14)
add_subheading(doc, "6.1 Liver Function Tests (LFTs)", MED_BLUE, 11.5)
lft_rows = [
["ALT (SGPT)", "↑↑↑ markedly elevated (>10× ULN)", "Most sensitive marker of hepatocellular injury"],
["AST (SGOT)", "↑↑↑ elevated (slightly < ALT)", "Hepatocellular damage; AST:ALT >2 suggests alcoholic hepatitis"],
["Serum Bilirubin", "↑ Total (direct + indirect)", "Impaired conjugation and excretion"],
["Alkaline Phosphatase", "Mildly elevated", "Cholestatic component"],
["Serum Albumin", "↓ (severe/chronic disease)", "Impaired protein synthesis"],
["Prothrombin Time (INR)", "Prolonged (severe disease)", "Impaired synthesis of clotting factors (II, V, VII, X)"],
["GGT", "Mildly elevated", "Hepatocellular/cholestatic marker; elevated in alcohol use"],
]
make_table(doc, ["Test", "Finding", "Significance"], lft_rows, [1.4, 2.0, 3.4], '1A346B')
add_subheading(doc, "6.2 Serological Diagnosis", MED_BLUE, 11.5)
sero_rows = [
["HAV", "Anti-HAV IgM", "Active/recent infection (acute)"],
["HAV", "Anti-HAV IgG", "Past infection or vaccination (immunity)"],
["HBV", "HBsAg", "Active infection (acute or chronic) — 1st marker to appear"],
["HBV", "Anti-HBs", "Recovery or successful vaccination"],
["HBV", "HBeAg", "High infectivity, active replication"],
["HBV", "Anti-HBc IgM", "Acute HBV infection; also positive in window period"],
["HBV", "Anti-HBc IgG", "Past or chronic infection (lifelong marker)"],
["HBV", "HBV DNA (PCR)", "Active viral replication; monitors treatment response"],
["HCV", "Anti-HCV", "Exposure (acute or chronic); does NOT confirm active infection alone"],
["HCV", "HCV RNA (PCR)", "Confirms active infection; gold standard; used to monitor treatment"],
["HCV", "HCV Genotype", "Guides treatment duration and regimen selection"],
["HDV", "Anti-HDV IgM/IgG", "HDV infection (only in HBsAg+ patients)"],
["HEV", "Anti-HEV IgM", "Acute HEV infection"],
]
make_table(doc, ["Virus", "Marker", "Interpretation"], sero_rows, [0.7, 1.8, 4.3], '1E6EBE')
add_subheading(doc, "6.3 Other Investigations", MED_BLUE, 11.5)
add_bullet(doc, "USG Abdomen (First-line imaging): Hepatomegaly, echogenicity, splenomegaly, ascites, bile duct dilation (rule out obstructive jaundice)")
add_bullet(doc, "Transient Elastography (FibroScan): Non-invasive liver stiffness/fibrosis measurement in chronic disease")
add_bullet(doc, "CT/MRI: Rule out HCC; assess portal hypertension")
add_bullet(doc, "Liver Biopsy: Staging chronic hepatitis; uncertain diagnosis; findings: ballooning degeneration, lobular inflammation, Kupffer cell hyperplasia")
add_bullet(doc, "CBC: Leukopenia with relative lymphocytosis; atypical lymphocytes (EBV-related hepatitis)")
add_bullet(doc, "Urinalysis: Bilirubinuria (dark urine); urobilinogen changes")
# ========== 7. TREATMENT GOALS ==========
add_colored_heading(doc, "7. TREATMENT GOALS", 1, DARK_BLUE, 14)
goals_rows = [
["Acute HAV/HEV", "Symptomatic relief; prevent complications; avoid hepatotoxic drugs; self-limiting"],
["Chronic HBV", "Suppress HBV DNA to undetectable; HBeAg seroconversion; normalize ALT; prevent cirrhosis and HCC; lifelong suppression usually required"],
["Chronic HCV", "Achieve SVR (Sustained Virologic Response) = undetectable HCV RNA 12 weeks post-treatment = functional cure (>95% cure rate with DAAs)"],
["Jaundice Management", "Identify and treat underlying cause; relieve pruritus; monitor bilirubin levels"],
["Fulminant Hepatitis", "ICU support; treat complications (encephalopathy, coagulopathy); liver transplant evaluation"],
["Long-term", "Prevent cirrhosis, liver failure, HCC; reduce transmission; vaccinate contacts"],
]
make_table(doc, ["Goal", "Details"], goals_rows, [1.8, 5.0], '007A87')
# ========== 8. NON-PHARMACOLOGICAL TREATMENT ==========
add_colored_heading(doc, "8. NON-PHARMACOLOGICAL TREATMENT", 1, DARK_BLUE, 14)
nonpharm = [
("Rest", "Bed rest during symptomatic acute phase; gradual return to normal activity as symptoms resolve; avoid strenuous exercise until ALT normalizes"),
("Diet", "High-calorie, high-carbohydrate diet; adequate protein (white meat preferred); low-fat diet (fat intolerance due to reduced bile); small, frequent meals; low-sodium (1.5 g/day) if ascites; fluid restriction (1.5 L/day) if hyponatremia"),
("Alcohol", "Complete abstinence — even small amounts worsen hepatocellular damage and impair recovery"),
("Hydration", "Adequate oral hydration; IV fluids if vomiting is severe (Ringer's lactate or Normal saline)"),
("Drugs to avoid", "Hepatotoxic drugs (paracetamol in large doses, NSAIDs); sedatives/hypnotics (may precipitate encephalopathy in severe disease); drugs requiring hepatic metabolism"),
("Isolation", "HAV/HEV: Enteric precautions (hand hygiene, food safety); HBV/HCV/HDV: Universal blood/body fluid precautions; standard PPE"),
("Education", "Transmission prevention (safe sex, no needle sharing); vaccination of contacts; regular follow-up; report jaundice/worsening symptoms"),
("Vaccination", "HAV vaccine/immunoglobulin for close contacts; HBV vaccine + HBIg for neonates of HBsAg+ mothers within 12 hours of birth"),
]
nonpharm_rows = [[t, d] for t, d in nonpharm]
make_table(doc, ["Measure", "Details"], nonpharm_rows, [1.4, 5.4], '1A346B')
# ========== 9. PHARMACOLOGICAL TREATMENT ==========
add_colored_heading(doc, "9. PHARMACOLOGICAL TREATMENT", 1, DARK_BLUE, 14)
add_body(doc, "Pharmacological treatment of viral hepatitis is indicated for chronic HBV and HCV. Acute HAV and HEV are managed supportively. The main drug categories are: (A) Nucleoside/Nucleotide Analogues for HBV, (B) Interferons for HBV/HCV, and (C) Direct-Acting Antivirals (DAAs) for HCV.", size=10.5)
# ---- SECTION A: HBV NAs ----
add_subheading(doc, "SECTION A: HEPATITIS B — Nucleoside/Nucleotide Analogues (NAs)", DARK_BLUE, 12)
add_body(doc, "NAs are oral agents that mimic natural nucleosides/nucleotides and competitively inhibit HBV reverse transcriptase (polymerase), blocking viral DNA synthesis. They suppress HBV replication but do NOT eradicate cccDNA (covalently closed circular DNA), so therapy is often lifelong or long-term. Key advantage: oral, once-daily, good tolerability.", size=10)
# Drug 1: Entecavir
add_subheading(doc, "Drug 1: ENTECAVIR (ETV)", TEAL, 11.5)
add_body(doc, "Class: Nucleoside analogue (guanosine analogue) | Preferred first-line agent", bold=True, size=10)
add_code_block(doc, """MOA FLOWCHART:
Entecavir (prodrug)
↓ Intracellular phosphorylation by cellular kinases
Entecavir Triphosphate (active form)
↓ Competitive inhibition of HBV DNA Polymerase/Reverse Transcriptase
├─ Inhibits priming of HBV DNA synthesis
├─ Inhibits reverse transcription of negative-strand DNA
└─ Inhibits synthesis of positive-strand HBV DNA
↓
↓ HBV DNA → Reduced hepatic inflammation → Prevention of cirrhosis/HCC""")
etv_rows = [
["Dose", "0.5 mg orally OD (treatment-naive); 1 mg OD (lamivudine-resistant) — on EMPTY STOMACH"],
["Indication", "Chronic hepatitis B in adults and children ≥2 years with evidence of active viral replication"],
["ADR", "Headache, fatigue, upper abdominal pain, dizziness; Lactic acidosis (rare but serious); Hepatitis flare on discontinuation"],
["Drug Interactions", "Nephrotoxic drugs may ↑ ETV concentrations; coadminister cautiously with agents altering renal function"],
["Contraindications", "Hypersensitivity; CrCl <50 mL/min (dose adjustment required); AVOID abrupt discontinuation; caution in lamivudine-resistant (cross-resistance — use 1 mg dose)"],
["Special Notes", "High barrier to resistance; preferred in cirrhosis; NOT for HIV/HBV coinfection as monotherapy (selects HIV resistance)"],
]
make_table(doc, ["Parameter", "Details"], etv_rows, [1.5, 5.3], '007A87')
# Drug 2: TDF
add_subheading(doc, "Drug 2: TENOFOVIR DISOPROXIL FUMARATE (TDF)", TEAL, 11.5)
add_body(doc, "Class: Nucleotide analogue (adenosine monophosphate analogue) | Preferred first-line agent", bold=True, size=10)
add_code_block(doc, """MOA FLOWCHART:
Tenofovir Disoproxil Fumarate (ester prodrug, oral bioavailability ~25%; ↑ with high-fat meal)
↓ Absorbed and converted to Tenofovir in blood
↓ Intracellular phosphorylation → Tenofovir Diphosphate (active)
↓ Competitive inhibition of HBV Reverse Transcriptase (also HIV RT)
↓ CHAIN TERMINATION → No new HBV DNA → ↓ Viral load""")
tdf_rows = [
["Dose", "300 mg orally OD (with or without food; food ↑ absorption)"],
["Indication", "Chronic HBV (adults, children ≥2 yrs); HIV; HBV/HIV co-infection (key agent in ART)"],
["ADR", "Nausea, diarrhea, abdominal pain; NEPHROTOXICITY (proximal tubular dysfunction, Fanconi syndrome — ↓ phosphate, glycosuria, amino aciduria); Decreased bone mineral density/Osteomalacia; Lactic acidosis (rare but serious)"],
["Drug Interactions", "NSAIDs/aminoglycosides (additive nephrotoxicity); Atazanavir+ritonavir ↑ TDF levels; Didanosine (ddI) ↑ levels → pancreatitis (avoid coadministration); ↑ tenofovir with velpatasvir-containing regimens"],
["Contraindications", "CrCl <15 mL/min without dialysis; prefer TAF in patients with bone disease or renal impairment; monitor renal function and bone density regularly"],
]
make_table(doc, ["Parameter", "Details"], tdf_rows, [1.5, 5.3], '007A87')
# Drug 3: TAF
add_subheading(doc, "Drug 3: TENOFOVIR ALAFENAMIDE (TAF)", TEAL, 11.5)
add_body(doc, "Class: Nucleotide analogue — newer prodrug of tenofovir with improved safety profile | Preferred over TDF for renal/bone disease", bold=True, size=10)
add_code_block(doc, """MOA FLOWCHART:
TAF (phosphonoamidate prodrug — greater intracellular delivery to hepatocytes)
↓ Preferential uptake and conversion in hepatocytes → Tenofovir Diphosphate
↓ Same mechanism as TDF — HBV RT inhibition → Chain termination
(Plasma tenofovir levels 10× LOWER than TDF → ↓ renal/bone toxicity)""")
taf_rows = [
["Dose", "25 mg orally OD (with food)"],
["Indication", "Chronic HBV in adults; preferred over TDF in patients with renal impairment or osteoporosis"],
["ADR", "Nausea, abdominal pain, fatigue; LESS nephrotoxicity and bone effects than TDF; weight gain (slightly more than TDF)"],
["Drug Interactions", "P-gp inducers (rifampin) ↓ TAF levels; not for use with other TAF-containing regimens"],
["Contraindications", "Severe hepatic impairment (Child-Pugh C); abrupt discontinuation may cause hepatitis flare"],
]
make_table(doc, ["Parameter", "Details"], taf_rows, [1.5, 5.3], '007A87')
# Drug 4: Lamivudine
add_subheading(doc, "Drug 4: LAMIVUDINE (3TC)", TEAL, 11.5)
add_body(doc, "Class: Nucleoside analogue (cytidine analogue) | Non-preferred — LOW barrier to resistance", bold=True, size=10)
add_code_block(doc, """MOA FLOWCHART:
Lamivudine → Intracellular phosphorylation → Lamivudine Triphosphate
↓ Competitive inhibition of HBV Reverse Transcriptase (also HIV RT)
↓ Chain termination → ↓ HBV DNA
⚠ HIGH RESISTANCE RATE: YMDD mutation → ~24% at 1 year, ~70% at 5 years""")
lam_rows = [
["Dose", "100 mg orally OD (HBV); 150 mg BD or 300 mg OD (HIV)"],
["Indication", "Chronic HBV (third-line; no longer preferred); HIV; HBV/HIV coinfection as part of ART"],
["ADR", "Headache, nausea, diarrhea, dizziness, myalgia; pancreatitis; lactic acidosis; HIGH resistance rate"],
["Drug Interactions", "Co-trimoxazole ↑ lamivudine levels; avoid drugs causing pancreatitis (ddI, alcohol, pentamidine)"],
["Contraindications", "Monotherapy in HBV/HIV co-infected (selects resistant HIV); not recommended as preferred 1st-line HBV agent (resistance)"],
]
make_table(doc, ["Parameter", "Details"], lam_rows, [1.5, 5.3], '007A87')
# Drug 5: Adefovir
add_subheading(doc, "Drug 5: ADEFOVIR DIPIVOXIL", TEAL, 11.5)
add_body(doc, "Class: Nucleotide analogue (adenine analogue) | Third-line agent — use only for lamivudine-resistant HBV", bold=True, size=10)
adef_rows = [
["Dose", "10 mg orally OD — optimal dose; higher doses (>10 mg) are nephrotoxic"],
["Indication", "Chronic HBV especially lamivudine-resistant cases; not preferred for first-line therapy"],
["ADR", "Nephrotoxicity (proximal renal tubular dysfunction), Fanconi syndrome, lactic acidosis; resistance develops (~4–6% at 3 yrs, ~30% at 5 yrs — rtN236T, rtA181V mutations)"],
["Drug Interactions", "Ibuprofen ↑ adefovir AUC (~23%); nephrotoxic agents (aminoglycosides, cyclosporine, tacrolimus)"],
["Contraindications", "Renal impairment requires dose adjustment; avoid doses >10 mg/day"],
]
make_table(doc, ["Parameter", "Details"], adef_rows, [1.5, 5.3], '007A87')
# ---- SECTION B: INTERFERONS ----
add_subheading(doc, "SECTION B: INTERFERONS — Immunomodulators", DARK_BLUE, 12)
add_body(doc, "Interferons are endogenous cytokines with antiviral AND immunomodulatory properties. Pegylated interferon (PEG-IFN) has longer half-life (once-weekly dosing) due to attachment of polyethylene glycol. Advantage: finite treatment duration with higher HBeAg seroconversion. Disadvantage: parenteral route, significant side effects, contraindicated in decompensated disease.", size=10)
# Drug 6: PEG-IFN
add_subheading(doc, "Drug 6: PEGYLATED INTERFERON ALFA-2a (PEG-IFN-α-2a)", TEAL, 11.5)
add_body(doc, "Class: Immunomodulator — Pegylated interferon | Used in HBV and HCV (older HCV therapy now largely replaced by DAAs)", bold=True, size=10)
add_code_block(doc, """MOA FLOWCHART:
PEG-IFN-α-2a (SC injection)
↓ Binds type I interferon receptor (IFNAR) on hepatocytes
↓ Activates JAK1/TYK2 kinases → STAT1/STAT2 phosphorylation
↓ ISGF3 complex formation → Enters nucleus → Upregulates ISGs (Interferon-Stimulated Genes)
├─ DIRECT ANTIVIRAL EFFECTS:
│ ├─ Activates 2',5'-Oligoadenylate synthetase (OAS) → RNase L → Degrades viral RNA
│ └─ Activates Protein Kinase R (PKR) → Phosphorylates eIF2α → Inhibits viral protein synthesis
└─ IMMUNOMODULATORY EFFECTS:
├─ ↑ NK cell cytotoxicity against infected hepatocytes
├─ ↑ CD8+ cytotoxic T lymphocyte (CTL) activity
└─ ↑ MHC class I expression → Better immune recognition of infected hepatocytes
↓
↓ HBV/HCV replication + Enhanced immune clearance → ↓ Viral load""")
pegifn_rows = [
["Dose (HBV)", "180 mcg SC ONCE WEEKLY × 48 weeks"],
["Dose (HCV)", "180 mcg SC once weekly + Ribavirin × 24–48 weeks (older therapy; now replaced by DAAs in most cases)"],
["Indication", "Chronic HBV (preferred for patients wanting finite therapy; younger patients without cirrhosis; HBeAg-positive with active disease); HCV (historical; replaced by DAAs)"],
["ADR", "FLU-LIKE SYNDROME (fever, chills, myalgia, headache — especially early doses; pre-treatment with paracetamol helps); Fatigue, depression, suicidal ideation (MONITOR MENTAL HEALTH); Myelosuppression (neutropenia, thrombocytopenia — ↑ infection/bleeding risk); Alopecia; Thyroid dysfunction (hypothyroid or hyperthyroid); Autoimmune reactions; Injection site reactions; Irritability, insomnia"],
["Drug Interactions", "Theophylline: PEG-IFN inhibits CYP1A2 → ↑ theophylline toxicity (↑ seizures, arrhythmia); Myelosuppressive agents: additive bone marrow suppression; Immunosuppressants: reduced efficacy"],
["Contraindications", "DECOMPENSATED CIRRHOSIS (Child-Pugh >6) — risk of hepatic decompensation/fatal flares; Autoimmune hepatitis; Severe psychiatric illness (depression, suicidal ideation); Uncontrolled seizure disorder; Bone marrow suppression; Severe cardiac/pulmonary disease; PREGNANCY (Category C); Hypersensitivity"],
]
make_table(doc, ["Parameter", "Details"], pegifn_rows, [1.5, 5.3], '007A87')
# ---- SECTION C: HCV DAAs ----
add_subheading(doc, "SECTION C: HEPATITIS C — DIRECT-ACTING ANTIVIRALS (DAAs)", DARK_BLUE, 12)
add_body(doc, "DAAs target specific non-structural (NS) proteins of HCV essential for viral replication. Key advantages: oral administration, 8–12 week duration, >95% cure (SVR) rates, excellent tolerability, pangenotypic coverage with newer agents. Three classes based on target:", size=10)
add_code_block(doc, """HCV REPLICATION TARGETS FOR DAA THERAPY:
HCV RNA → Translation → Polyprotein
↓
┌─────────────────────────────────┐
│ NS3/4A Serine PROTEASE │ ← Inhibited by: Glecaprevir (-previr)
│ (cleaves polyprotein into │
│ functional viral proteins) │
└─────────────────────────────────┘
↓
┌─────────────────────────────────┐
│ NS5A PROTEIN │ ← Inhibited by: Ledipasvir, Velpatasvir,
│ (forms replication complex; │ Pibrentasvir (-asvir)
│ viral assembly) │
└─────────────────────────────────┘
↓
┌─────────────────────────────────┐
│ NS5B RNA-DEPENDENT RNA POLYMERASE│ ← Inhibited by: Sofosbuvir (-buvir)
│ (copies HCV RNA genome) │
└─────────────────────────────────┘
↓
New HCV RNA genomes → Virion assembly → Viral release""")
# Drug 7: Sofosbuvir
add_subheading(doc, "Drug 7: SOFOSBUVIR (SOF)", TEAL, 11.5)
add_body(doc, "Class: NS5B RNA Polymerase Inhibitor (Nucleotide analogue) | Backbone of most HCV regimens", bold=True, size=10)
add_code_block(doc, """MOA FLOWCHART:
Sofosbuvir (prodrug) — administered orally with food
↓ Absorbed in intestine → Rapid conversion to GS-331007 metabolite in plasma
↓ GS-331007 taken up by hepatocytes
↓ Phosphorylation by cellular kinases → GS-461203 (uridine analog 5'-triphosphate) — ACTIVE form
↓ GS-461203 incorporated by NS5B RNA Polymerase into growing HCV RNA strand
↓ CHAIN TERMINATION (no 3'-OH group) → HCV RNA synthesis stops
↓ ↓ HCV RNA → SVR >95% when combined with NS5A inhibitor""")
sof_rows = [
["Dose", "400 mg orally OD with food; used in fixed-dose combinations only (SOF/LDV, SOF/VEL, SOF/VEL/VOX)"],
["Indication", "Chronic HCV (all genotypes when combined with NS5A inhibitor); used in combinations (Harvoni, Epclusa, Vosevi)"],
["ADR", "Fatigue, headache, asthenia, nausea; with ribavirin: hemolytic anemia, rash, insomnia; bradycardia (with amiodarone — SERIOUS)"],
["Drug Interactions", "AMIODARONE (any route) + SOF-containing regimen → FATAL bradycardia and heart block (CONTRAINDICATED); P-gp inducers (rifampin, carbamazepine, St. John's wort, phenytoin) → ↓ SOF levels → treatment failure (AVOID); Tipranavir/ritonavir: ↓ SOF (avoid)"],
["Contraindications", "Coadministration with amiodarone; P-gp/strong CYP inducers; severe renal impairment with SOF/VEL/VOX (CrCl <30 mL/min); pregnancy (ribavirin-containing regimens absolutely contraindicated)"],
]
make_table(doc, ["Parameter", "Details"], sof_rows, [1.5, 5.3], '007A87')
# Drug 8: SOF/LDV (Harvoni)
add_subheading(doc, "Drug 8: LEDIPASVIR + SOFOSBUVIR (Harvoni) — SOF/LDV", TEAL, 11.5)
add_body(doc, "Class: NS5B Inhibitor + NS5A Inhibitor | Fixed-dose combination for HCV genotypes 1, 4, 5, 6", bold=True, size=10)
add_code_block(doc, """MOA FLOWCHART:
LEDIPASVIR (NS5A Inhibitor) SOFOSBUVIR (NS5B Inhibitor)
↓ ↓
Binds NS5A protein Inhibits NS5B RNA polymerase
↓ ↓
Disrupts replication complex Chain termination of HCV RNA
+ Inhibits viral assembly ↓
└─────────────────┬──────────────────────┘
↓
DUAL mechanism → ↓ HCV replication → SVR >95%
(Genotypes 1, 4, 5, 6 — 8-12 weeks)""")
ldv_rows = [
["Dose", "SOF 400 mg / LDV 90 mg — 1 tablet OD; 8 weeks (GT1 treatment-naive, no cirrhosis, HCV RNA <6 million IU/mL); 12 weeks (standard)"],
["Indication", "HCV Genotypes 1, 4, 5, 6; treatment-naive and treatment-experienced"],
["ADR", "Fatigue, headache, nausea, insomnia, asthenia, diarrhea"],
["Drug Interactions", "ANTACIDS (Al/Mg-based): take Harvoni ≥4 hours before or after; H2 blockers: take simultaneously with food or 12 hours apart; PPIs: avoid (reduce LDV absorption — if must use, omeprazole equivalent ≤20 mg); Rifampin/carbamazepine/St. John's wort: ↓ both components (AVOID); Rosuvastatin ↑ plasma levels (limit dose/avoid); Digoxin ↑ (monitor)"],
["Contraindications", "Coadministration with strong P-gp inducers (rifampin); amiodarone (see sofosbuvir); decompensated cirrhosis may require ribavirin addition"],
]
make_table(doc, ["Parameter", "Details"], ldv_rows, [1.5, 5.3], '007A87')
# Drug 9: GLE/PIB (Mavyret)
add_subheading(doc, "Drug 9: GLECAPREVIR + PIBRENTASVIR (Mavyret) — GLE/PIB", TEAL, 11.5)
add_body(doc, "Class: NS3/4A Protease Inhibitor + NS5A Inhibitor | PANGENOTYPIC (all genotypes 1–6)", bold=True, size=10)
add_code_block(doc, """MOA FLOWCHART:
GLECAPREVIR (NS3/4A Protease Inhibitor) PIBRENTASVIR (NS5A Inhibitor)
↓ ↓
Binds NS3/4A serine protease active site Binds NS5A protein (domain I)
↓ ↓
Prevents HCV polyprotein cleavage Disrupts replication complex
(NS4A, NS4B, NS5A, NS5B cannot be + Inhibits viral assembly/release
released as functional proteins) ↓
└────────────────┬─────────────────────────┘
↓
PANGENOTYPIC dual NS3/4A + NS5A inhibition
↓
SVR >97% in all genotypes 1-6 | Preferred: NO RIBAVIRIN needed""")
mavyret_rows = [
["Dose", "GLE 300 mg / PIB 120 mg (3 tablets) OD WITH FOOD — must be taken with food for optimal absorption"],
["Duration", "8 weeks (treatment-naive, no cirrhosis, GT 1-6); 8–12 weeks (compensated cirrhosis); 12–16 weeks (DAA-experienced); preferred for short 8-week pangenotypic therapy"],
["Indication", "Chronic HCV genotypes 1-6 (pangenotypic); preferred for patients with renal impairment (NO dose adjustment needed); post-kidney transplant; HIV/HCV co-infection"],
["ADR", "Headache, fatigue, nausea; Pruritus; Elevated indirect (unconjugated) bilirubin (not hepatotoxic — inhibits OATP transporters for bilirubin)"],
["Drug Interactions", "P-gp inducers (RIFAMPIN: avoid — AUC decreases >90%); Statins: ↑ statin plasma levels via OATP1B1/1B3 inhibition → MYOPATHY risk (avoid lovastatin/simvastatin; caution with atorvastatin/rosuvastatin); CYCLOSPORINE >100 mg/day: ↑ GLE levels 14-fold (CONTRAINDICATED); Dabigatran/digoxin: ↑ levels (P-gp substrate); Ethinyl estradiol OCP: risk of ALT elevation (AVOID — use alternative contraception)"],
["Contraindications", "Decompensated cirrhosis (Child-Pugh B/C); rifampin or strong P-gp inducers; severe hepatic impairment; cyclosporine >100 mg/day; ethinyl estradiol-containing contraceptives"],
]
make_table(doc, ["Parameter", "Details"], mavyret_rows, [1.5, 5.3], '007A87')
# Drug 10: SOF/VEL (Epclusa)
add_subheading(doc, "Drug 10: SOFOSBUVIR + VELPATASVIR (Epclusa) — SOF/VEL", TEAL, 11.5)
add_body(doc, "Class: NS5B Inhibitor + NS5A Inhibitor | PANGENOTYPIC (genotypes 1–6)", bold=True, size=10)
add_code_block(doc, """MOA FLOWCHART:
VELPATASVIR (NS5A Inhibitor) + SOFOSBUVIR (NS5B Inhibitor)
↓ ↓
Inhibits NS5A function Chain termination at NS5B
(replication complex + assembly) ↓
└───────────────┬─────────────────┘
↓
Pan-genotypic dual inhibition → SVR >95% genotypes 1-6
Velpatasvir metabolized by CYP2B6, CYP2C8, CYP3A4""")
epclusa_rows = [
["Dose", "SOF 400 mg / VEL 100 mg — 1 tablet OD; 12 weeks (all GT, with or without compensated cirrhosis); 12 weeks + weight-based Ribavirin (decompensated cirrhosis)"],
["Indication", "HCV GT 1-6 (pangenotypic); first-line; decompensated cirrhosis (with ribavirin); preferred when ribavirin is needed for advanced disease"],
["ADR", "Headache, fatigue, nausea, insomnia, asthenia; ribavirin-related: anemia"],
["Drug Interactions", "P-gp/CYP inducers (RIFAMPIN, St. John's wort, carbamazepine, phenytoin, phenobarbital): CONTRAINDICATED → ↓ VEL/SOF levels; Antacids/H2 blockers: ↓ VEL absorption (separate by ≥4 hours from antacids; take simultaneously with food with H2 blocker); EFAVIRENZ: ↓ VEL levels — avoid; AMIODARONE: cardiac risk (avoid); Tenofovir DF: ↑ tenofovir levels with velpatasvir (monitor renal function; avoid if CrCl <60 mL/min)"],
["Contraindications", "Amiodarone coadministration; P-gp/CYP3A4/2B6/2C8 inducers; Child-Pugh C without ribavirin regimen"],
]
make_table(doc, ["Parameter", "Details"], epclusa_rows, [1.5, 5.3], '007A87')
# Drug 11: Ribavirin
add_subheading(doc, "Drug 11: RIBAVIRIN (RBV)", TEAL, 11.5)
add_body(doc, "Class: Nucleoside analogue (guanosine analogue) | Adjunct agent — NEVER used as monotherapy for HCV", bold=True, size=10)
add_code_block(doc, """MOA FLOWCHART:
Ribavirin → Intracellular phosphorylation → Ribavirin Triphosphate (active)
├─ Inhibits IMPDH (inosine monophosphate dehydrogenase)
│ → ↓ GTP (guanosine triphosphate) pool → ↓ Viral RNA synthesis
├─ RNA MUTAGENESIS (Error Catastrophe theory)
│ → Incorporates into viral RNA → Accumulates lethal mutations → Virus cannot replicate
└─ IMMUNOMODULATION
→ Shifts Th2 → Th1 cytokine response → ↑ cellular immunity against HCV
↓
Used in combination with SOF/VEL for decompensated cirrhosis and with PEG-IFN (older regimens)""")
riba_rows = [
["Dose", "Weight-based: <75 kg = 1000 mg/day; ≥75 kg = 1200 mg/day orally in 2 divided doses WITH FOOD (reduces nausea/anemia if taken with food)"],
["Indication", "Combined with SOF/VEL (decompensated cirrhosis); combined with PEG-IFN (older HCV regimens); retreatment of certain DAA failures"],
["ADR", "HEMOLYTIC ANEMIA (most significant, dose-limiting — ↓ Hb by 2–3 g/dL common; check CBC regularly); TERATOGENICITY (Category X — two forms of contraception required for 6 months after stopping in both males and females); Fatigue, insomnia, depression; Rash, pruritus; Cough (if inhaled form)"],
["Drug Interactions", "DIDANOSINE (ddI): ↑↑ risk of pancreatitis and lactic acidosis (CONTRAINDICATED); Zidovudine (AZT): additive anemia (avoid); Azathioprine: severe pancytopenia (caution)"],
["Contraindications", "PREGNANCY (Category X — teratogenic; 6 months contraception required post-treatment); Hemoglobin <10 g/dL before treatment; Severe renal impairment (CrCl <50 mL/min); Hemolytic anemia or hemoglobinopathies; Significant cardiac disease (anemia risk)"],
]
make_table(doc, ["Parameter", "Details"], riba_rows, [1.5, 5.3], '007A87')
# Supportive drugs
add_subheading(doc, "SECTION D: SUPPORTIVE / SYMPTOMATIC DRUGS", DARK_BLUE, 12)
supp_rows = [
["Ursodeoxycholic Acid (UDCA)", "Bile acid (hepatoprotective)", "13–15 mg/kg/day in 2-3 divided doses", "Replaces toxic bile acids with hydrophilic UDCA → stabilizes hepatocyte membranes; cytoprotective; immunomodulatory; stimulates bile flow", "Diarrhea, nausea; initial pruritus worsening", "Biliary obstruction, calcified gallstones, acute cholecystitis"],
["Cholestyramine", "Bile acid sequestrant", "4–8 g BD–QID before meals", "Binds bile acids in gut → prevents reabsorption → ↓ pruritus (first-line for cholestatic pruritus)", "Constipation, fat-soluble vitamin malabsorption; blocks drug absorption (take other drugs 1h before or 4-6h after)", "Biliary obstruction (bile acids not in gut); phenylketonuria (some formulations)"],
["Rifampicin", "PXR agonist (antibiotic)", "150–300 mg/day", "Activates pregnane X receptor → ↑ hepatic enzymes for bile acid metabolism → ↓ circulating bile acids → ↓ pruritus (second-line)", "Hepatotoxicity, red-orange discoloration of body fluids, induction of CYP enzymes", "Hypersensitivity; severe hepatic impairment"],
["Silymarin (Milk Thistle)", "Herbal hepatoprotective", "140 mg TDS", "Antioxidant; free radical scavenging; inhibits lipid peroxidation; stabilizes hepatocyte membranes; anti-fibrotic", "GI disturbances (mild)", "Hypersensitivity to Asteraceae family"],
]
make_table(doc, ["Drug", "Class", "Dose", "MOA/Use", "ADR", "Contraindications"], supp_rows, [1.3, 1.1, 0.9, 1.7, 1.4, 1.3], '1E6EBE')
# ========== 10. SUMMARY CHART ==========
add_colored_heading(doc, "10. PHARMACOLOGICAL TREATMENT — MASTER SUMMARY CHART", 1, DARK_BLUE, 14)
add_subheading(doc, "10A. Hepatitis B Drug Summary", MED_BLUE, 11.5)
hbv_sum_rows = [
["Entecavir", "NA — Guanosine", "0.5 mg OD naive\n1 mg OD (LAM-R)", "✓ HBV naive/resistant", "Lactic acidosis, headache, fatigue", "Nephrotoxic drugs", "CrCl <50 (adjust); no abrupt stop; high resistance barrier"],
["TDF", "NA — Adenosine nucleotide", "300 mg OD", "✓ HBV, HIV, co-infection", "Nephrotoxicity, Fanconi, osteomalacia, lactic acidosis", "NSAIDs, ddI, atazanavir/r", "Renal impairment (adjust); prefer TAF in bone/renal disease"],
["TAF", "NA — Adenosine nucleotide (prodrug)", "25 mg OD (with food)", "✓ HBV (preferred in renal/bone disease)", "Weight gain; less nephrotox than TDF", "Rifampin ↓ levels", "Severe hepatic failure; no abrupt stop"],
["Lamivudine", "NA — Cytidine", "100 mg OD (HBV)", "HBV (not preferred—resistance)", "High resistance (YMDD), pancreatitis, LA", "Co-trimoxazole ↑ levels", "No HBV/HIV monotherapy; not preferred 1st-line"],
["Adefovir", "NA — Adenine nucleotide", "10 mg OD", "HBV (LAM-resistant, 3rd line)", "Nephrotoxicity, Fanconi, LA", "Ibuprofen ↑ levels", "Renal impairment; >10 mg nephrotoxic"],
["PEG-IFN-α-2a", "Immunomodulator", "180 mcg SC weekly × 48 wks", "✓ HBV (finite therapy), historical HCV", "Flu-like, depression, neutropenia, thyroid dysfunction, alopecia", "Theophylline↑; myelosuppressants", "Decompensated cirrhosis; autoimmune hep; severe psych; PREGNANCY"],
]
make_table(doc, ["Drug", "Class", "Dose", "Indication", "Key ADR", "Drug Interactions", "Contraindications"], hbv_sum_rows, [1.0, 1.0, 0.9, 1.0, 1.3, 1.0, 1.5], '1A346B')
add_subheading(doc, "10B. Hepatitis C (DAA) Summary", MED_BLUE, 11.5)
hcv_sum_rows = [
["Sofosbuvir (SOF)", "NS5B inhibitor", "400 mg OD", "GT 1–6 (in combos)", "12 wks (with NS5A inhibitor)", "Fatigue, headache", "AMIODARONE (fatal bradycardia); rifampin; carbamazepine", "Amiodarone; P-gp inducers; severe renal+SOF/VEL/VOX"],
["SOF/LDV (Harvoni)", "NS5B + NS5A", "400/90 mg OD", "GT 1,4,5,6", "8–12 weeks", "Fatigue, headache, nausea", "Antacids (space 4h); rifampin; St. John's wort; rosuvastatin", "P-gp inducers; amiodarone; decompensated (±RBV needed)"],
["GLE/PIB (Mavyret)", "NS3/4A + NS5A", "300/120 mg OD with food", "GT 1–6 (pangenotypic)", "8 wks (naive, no cirrhosis)", "Headache, pruritus, ↑indirect bili", "RIFAMPIN (avoid); statins (myopathy); cyclosporine >100 mg (CI); ethinyl estradiol (avoid)", "Decompensated cirrhosis; rifampin; Child-Pugh B/C; cyclosporine >100 mg"],
["SOF/VEL (Epclusa)", "NS5B + NS5A", "400/100 mg OD", "GT 1–6 (pangenotypic)", "12 wks (±RBV for decomp)", "Headache, fatigue, nausea", "Rifampin/inducers (CI); antacids (space 4h); efavirenz ↓VEL; amiodarone", "Amiodarone; P-gp/CYP inducers; efavirenz; decompensated±RBV"],
["SOF/VEL/VOX (Vosevi)", "NS5B+NS5A+NS3/4A", "400/100/100 mg OD", "GT 1–6 retreatment", "12 wks", "Headache, fatigue, nausea, diarrhea", "Same as SOF/VEL; statin interactions (OATP)", "P-gp inducers; amiodarone; decompensated cirrhosis"],
["Ribavirin", "Nucleoside analogue (adjunct)", "Weight-based 1000–1200 mg/day (2 doses)", "Adjunct with SOF/VEL for decomp; with PEG-IFN", "With DAAs/IFN", "HEMOLYTIC ANEMIA; teratogenicity; fatigue; rash", "DIDANOSINE (CI — pancreatitis/LA); AZT (↑anemia); azathioprine", "PREGNANCY (Category X); Hb <10 g/dL; severe renal impairment; hemolytic anemia"],
]
make_table(doc, ["Drug", "Class", "Dose", "Genotype", "Duration", "Key ADR", "Drug Interactions", "Contraindications"], hcv_sum_rows, [0.9, 0.9, 0.85, 0.8, 0.75, 1.0, 1.3, 1.3], '1A346B')
# ========== 11. COMPLICATIONS ==========
add_colored_heading(doc, "11. COMPLICATIONS OF VIRAL HEPATITIS", 1, DARK_BLUE, 14)
comp_rows = [
["Cirrhosis", "HBV, HCV, HDV", "Progressive hepatic fibrosis; portal hypertension; liver failure"],
["Hepatocellular Carcinoma (HCC)", "HBV (can cause HCC even without cirrhosis), HCV", "Screen every 6 months: AFP + USG in at-risk patients"],
["Fulminant Hepatic Failure", "HAV, HBV (co/superinfection with HDV), HEV (pregnancy)", "Encephalopathy, coagulopathy; ICU; liver transplant consideration"],
["Cryoglobulinemia", "HCV", "Mixed cryoglobulinemia; vasculitis; arthritis; glomerulonephritis; purpura"],
["Membranous Glomerulonephritis", "HBV", "Nephrotic syndrome — HBsAg deposition in glomerular basement membrane"],
["Aplastic Anemia", "HAV, HBV (rare)", "Post-hepatitis aplastic anemia — mechanism: autoimmune"],
["Portal Hypertension", "Chronic HBV/HCV/HDV → cirrhosis", "Esophageal/gastric varices, ascites, splenomegaly, hepatic encephalopathy"],
]
make_table(doc, ["Complication", "Associated Virus", "Details"], comp_rows, [1.6, 1.5, 3.7], '1E6EBE')
# ========== 12. PREVENTION ==========
add_colored_heading(doc, "12. PREVENTION", 1, DARK_BLUE, 14)
prev_rows = [
["HAV", "2-dose vaccination (0, 6–12 months); Hepatitis A IG within 2 weeks of exposure; hand hygiene; safe food/water"],
["HBV", "3-dose vaccination (0, 1, 6 months); HBIg + vaccine for neonates of HBsAg+ mothers (within 12 hours of birth); safe sex (condoms); no needle sharing; blood/organ screening"],
["HCV", "NO vaccine available; Harm reduction programs (clean needles, NSPs); universal precautions; blood screening; no needle sharing"],
["HDV", "Prevented by HBV vaccination (HDV requires HBV co-infection); HBIg for post-exposure HBV prophylaxis"],
["HEV", "Hecolin® vaccine (available in China); safe drinking water; food hygiene; hand washing; avoid undercooked pork/wild game"],
]
make_table(doc, ["Hepatitis", "Prevention"], prev_rows, [0.9, 5.9], '007A87')
# ========== MNEMONICS ==========
add_colored_heading(doc, "13. QUICK REVIEW — MNEMONICS & KEY POINTS", 1, DARK_BLUE, 14)
add_code_block(doc, """TRANSMISSION ROUTES: "B, C, D = Blood; A, E = Alimentary (fecal-oral)"
HBV FIRST-LINE (WHO/AASLD): "ETP" = Entecavir, Tenofovir (TDF/TAF), Peg-IFN
DAA CLASSES IN HCV — "3 + 5A + 5B":
NS3/4A Protease Inhibitors: Glecaprevir (-PREVIR)
NS5A Inhibitors: Ledipasvir, Velpatasvir, Pibrentasvir (-ASVIR)
NS5B Inhibitors: Sofosbuvir (-BUVIR)
RIBAVIRIN ADR MNEMONIC — "HATE":
H = Hemolytic anemia
A = Anemia (dose-limiting)
T = Teratogenic (Category X — 6 months contraception)
E = Excluded in pregnancy
JAUNDICE TYPES:
Pre-hepatic (hemolysis) = ↑ Unconjugated bilirubin; normal LFTs; dark urine absent
Hepatic (viral hepatitis) = ↑ Both types; ↑ ALT/AST; dark urine present
Post-hepatic (obstruction) = ↑ Conjugated bilirubin; ↑ ALP/GGT; pale stools; dark urine
CRITICAL DRUG INTERACTIONS TO REMEMBER:
• Sofosbuvir + AMIODARONE → Fatal bradycardia (ABSOLUTELY CONTRAINDICATED)
• Ribavirin + DIDANOSINE → Lactic acidosis/pancreatitis (CONTRAINDICATED)
• GLE/PIB + RIFAMPIN → Treatment failure (CONTRAINDICATED)
• GLE/PIB + CYCLOSPORINE >100mg → ↑ GLE 14-fold (CONTRAINDICATED)
• PEG-IFN + THEOPHYLLINE → Theophylline toxicity
• TDF + NSAIDs → Additive nephrotoxicity (MONITOR)
CONTRAINDICATION SUMMARY — PEG-IFN: "DAPS"
D = Decompensated cirrhosis
A = Autoimmune hepatitis
P = Psychiatric illness (severe)
S = Severe cardiac/bone marrow disease + Seizures + Pregnancy""")
add_separator(doc)
add_body(doc, "Sources: Katzung's Basic and Clinical Pharmacology 16th Ed. (p.1373+) | Goldman-Cecil Medicine | Harrison's Principles of Internal Medicine 22e | pharmdguru.com/viral-hepatitis-including-jaundice/ | PMC8218370 (Update on Management of Viral Hepatitis) | Medscape Hepatitis B/C Treatment Guidelines", italic=True, color=GREY, size=9)
doc.save('/tmp/workspace/viral-hepatitis-notes/Viral_Hepatitis_Therapeutics3_Notes.docx')
print("Document saved successfully!")
Running Command
cd /tmp/workspace/viral-hepatitis-notes && python3 create_notes.py 2>&1
Running Command
ls -lh /tmp/workspace/viral-hepatitis-notes/
give notes in word formate
The Word document was already created in our previous session! Here it is:
Viral Hepatitis Therapeutics3 Notes
Word Document · DOCX
The document includes all of the following sections:
- Introduction - Overview of viral hepatitis and jaundice
- Definition - Key terms table (viral hepatitis, acute, chronic, SVR, fulminant)
- Etiology - Comparison table (HAV, HBV, HCV, HDV, HEV) + risk factors
- Pathophysiology Flowcharts - Viral hepatitis pathway + jaundice types (pre/hepatic/post-hepatic)
- Clinical Features - 3-phase table (prodromal, icteric, convalescent) + signs
- Diagnosis - LFTs table, serological markers table, imaging
- Treatment Goals - Per hepatitis type
- Non-Pharmacological Treatment - Rest, diet, alcohol, isolation, vaccination
- Pharmacological Treatment - 11 drugs with:
- Drug class + short intro
- MOA flowchart (code-block style)
- Dose, Indication, ADR, Drug Interactions, Contraindications
- Master Summary Charts - HBV drugs + HCV DAA drugs in single reference tables
- Complications - Cirrhosis, HCC, cryoglobulinemia, etc.
- Prevention - Per hepatitis type
- Mnemonics - "ETP", "B,C,D=Blood; A,E=Alimentary", "HATE", "DAPS", critical drug interactions
This is a shared conversation. Sign in to Orris to start your own chat.